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Abstract 
The prevalence of overweight and obese individuals has been recognized globally for 
decades. Of all countries, United States has the highest rate of obesity. One third of its adult 
population is obese, and around two thirds are overweight. Moreover, childhood obesity has 
rapidly increased with 17% of children ages 2-19 are now obese. The American Medical 
Association (the nation’s leading physician’s organization) recently declared that obesity is a 
“disease”. Obesity increases the risk of metabolic related diseases, including type 2 diabetes, 
cardiovascular disease, fatty liver diseases and other human disease like female infertility, mental 
depression and even certain types of cancer. Obesity, characterized by excessive body weight, is 
often considered to result from an imbalance between energy intake and energy output. Either 
excessive food intake or insufficient physical activity can cause obesity. Abnormally elevated 
cholesterol, lipid and glucose levels due to disruption of metabolic hemostasis in obesity play 
causative roles in the development of metabolic diseases. Therefore, regulation of cholesterol, 
lipid and glucose levels in the body are critical for maintaining energy balance. During my Ph.D. 
thesis studies, I explored the function role of Farnesoid X receptor (FXR) and microRNA-34 
(miR-34a), as key transcriptional and post-transcriptional regulators respectively, in maintaining 
metabolic hemostasis and energy balance.  
Nuclear receptors (NRs) are lipophilic ligand-dependent transcriptional factors that 
regulate the expression of specific target genes involved in diverse biological pathways, 
including development, differentiation, cell proliferation, reproduction and metabolism. FXR is a 
member of the nuclear receptor superfamily. After a meal, FXR is activated by bile acids (BA) 
and plays a crucial role in maintaining bile acid, cholesterol, glucose and lipid levels through 
gene regulation. In addition to these functions, previous genome-wide analysis of hepatic FXR 
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binding sites by our laboratory revealed that binding of FXR was extensively detected in 
previously unknown categories of genes, including autophagy network genes and genes in the 
fibroblast growth factor-19 (FGF19) signaling pathway.  
MicroRNAs (miRs) are a class of small noncoding RNAs, usually 20-22 nucleotides long, 
first processed in the nucleus by the enzyme Drosha and then processed to its mature form in the 
cytoplasm by Dicer. MiRs usually function as negative post-transcriptional regulators by either 
inhibiting target protein translation or promoting degradation of target mRNAs by directly 
binding to the 3’UTR region of the mRNA. MiRs have been recognized as a distinct class of 
biological regulators with conserved functions and likely to target about 60% of mammalian 
genes. Moreover, aberrant expression of miRs occurs in many diseases, such as heart disease, 
cancer and obesity. In previous microRNA array analyses in wild-type (WT) mice and FXR 
knockout (FXR-KO) mice, our lab identified miR-34a as the hepatic miR most highly regulated 
by FXR and showed that FXR inhibits the expression of miR-34a indirectly through induction of 
the regulatory factor, Small Heterodimer Partner (Shp). Moreover, other researchers later showed 
that miR-34a is the most aberrantly elevated hepatic miR in obese mice and also is substantially 
elevated in diabetic human patients. Thus, in this thesis, my goal is to further understand the role 
of FXR and miR-34a as key metabolic regulators. There are four studies described in the 
following chapters: chapters 2 and 3 focus on aberrantly elevated miR-34a in liver and adipose 
tissue, respectively, in the obese state; chapters 4 and 5 are centered on the transcriptional 
regulation of FXR, repressing autophagy by inhibiting a fasted state regulator CREB and priming 
the liver for FGF19 signaling responses in the fed state, respectively. 
In chapter 2, I studied the function of hepatic miR-34a. As mentioned before, miR-34a 
levels are aberrantly elevated in obese mice and patients. My evidence indicated that βKlotho 
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(βKL), a membrane co-receptor for FGF19 signaling, is a direct target of miR-34a. FGF19 is a 
fed-state hormone. After a meal, BA-activated FXR transcriptionally induces expression of 
FGF19 which is synthesized and secreted in intestine and acts at the liver where it binds to the 
membrane FGFR4/βKL receptor complex and mediates postprandial responses under normal 
physiological conditions. However,  hepatic miR-34a is highly elevated in the obese state which 
results in repressed βKL expression, impaired FGF19-activated Erk signaling, and altered 
expression of FGF19 metabolic target genes. In vivo antisense inhibition of miR-34a in obese 
mice partially restored βKL levels and improved FGF19 target gene expression and resulted in 
beneficial metabolic outcomes such as weight loss and increased insulin sensitivity establishing 
the important role of miR-34a in metabolic disorders related to obesity.   
In chapter 3, I extended my studies on the function of miR-34a to adipose tissue, since 
βKL is also a co-receptor for another FGF, FGF21, which acts on adipose tissue to regulate 
metabolism. FGF21 is also an endocrine hormone that has lipid-lowering and insulin-sensitizing 
beneficial effects when administered to obese patients. FGF21 binds to the adipocyte membrane 
FGFR1/βKL receptor complex, and activates Erk signaling which results in induction of FGF21 
metabolic target genes. Besides βKL, I identified FGFR1 as a direct target of miR-34a. Other 
researchers had already reported that expression levels of βKL and FGFR1 in adipose tissue are 
strikingly decreased in obesity. Obesity is a FGF21-resistance state, but the underlying 
mechanisms were not known. In this study, I found that aberrantly elevated adipocyte miR-34a 
in obesity downregulated both βKL and FGFR1 expression, thereby impairing FGF21 signaling. 
Moreover, miR-34a inhibited brown fat formation by suppressing the browning activators and 
attenuation of FGF21 signaling. This was an important observation since brown fat is known to 
increase energy expenditure by generating heat through uncoupled respiration so that promotion 
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of brown fat would be desirable in obesity. Emerging evidence indicates that brown fat is 
substantially decreased while white fat is substantially increased in obesity, but the mechanisms 
underlying the decreased brown fat were unknown. Remarkably, I found that downregulation of 
miR-34a in obese mice dramatically increased beige depots (a form of brown fat produced in 
white fat that is distinct from classical brown fat), activated browning in brown adipose tissue, 
and reduced white fat. The substantial reduction in adiposity was associated with improved 
serum lipid profiles, increased mitochondria numbers and increased oxidative function. 
Collectively, the studies in chapter 2 and 3 revealed that miR-34a is a key factor that contributes 
to the FGF19-resistance and FGF21-resistance in liver and adipose tissue, respectively, that is 
observed in obesity. The striking beneficial results that I observed in vivo by inhibition of miR-
34a provide evidence for the therapeutic potential of treating obesity with anti-miR-34a.  
In chapter 4, in collaboration with Dr. Sunmi Seok, a post-doctoral researcher in 
Kemper’s lab, I explored the functional role of hepatic FXR in autophagy, as a fed-state 
activated regulator. Autophagy is essential for cellular survival and homeostasis under nutrient-
deprived fasting conditions, but must be suppressed in the nutrient-rich fed state. Short-term 
regulation of autophagy by nutrient-sensing kinases is well defined, but long-term transcriptional 
regulation is relatively unknown. Previous global ChIP-seq studies from our laboratory showed 
increased occupancy of FXR on genes in the autophagy network upon treatment with GW4064 
(a synthetic FXR agonist). We showed that the expression level of those autophagy genes were 
decreased, which suggests that FXR may repress autophagy genes upon feeding. In an analysis 
of common sequences near the FXR repressed autophagy genes, the CREB binding motif was 
identified as a likely transcriptional factor that binds to their promoter regions. In a combined 
analysis of mouse hepatic FXR and CREB ChIP-seq data, 78 autophagy-related genes had shared 
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FXR and CREB binding peaks among 230 genes in total, mostly in their promoter regions. 
Mechanistically, we showed that CREB upregulates autophagy genes by recruiting its 
coactivator CRTC2 under fasting conditions. Upon feeding, bile-acid activated FXR trans-
repressed these autophagy genes by disrupting the functional CREB/CRTC2 complex.  This 
study identifies the FXR/CREB axis as a novel, key physiological switch regulating autophagy 
that results in sustained nutrient regulation of autophagy during feeding/fasting cycles.   
Hepatic metabolic responses to a meal are regulated by an intricate interplay among 
intestinal, pancreatic and hepatic hormones and factors. In chapter 5, I examined whether FXR, 
which induces FGF19 synthesis in the intestine, also primes the liver to enhance FGF19 
signaling in the fed state. Our previous hepatic FXR Chip-seq data revealed that FXR has 
binding sites on FGF19 signaling component genes, especially the membrane co-receptor βKL. 
My preliminary data showed that FXR occupancy and expression of βKL increased after 
activation of FXR by GW4064 treatment. In addition, I showed that FXR-RXRα bind to the βKL 
gene by in vitro gel shift assays and that FXR up-regulates βKL by reporter-luciferase assays. 
More interestingly, my initial in vivo time course studies showed that FXR regulates FGF19 
synthesis, mostly from intestine, followed by the induction of βKL gene expression in the liver. 
Future studies will be needed to definitively test the hypothesis that FXR primes the liver for 
FGF19 function.   
In summary, in this thesis, I studied the functions of miR-34a and FXR as key metabolic 
regulators in modulating FGF19 and FGF21 signaling, stimulating browning of fat, inhibiting 
autophagy, and priming the liver for response to signals from the gut. I hope that the findings 
from the miR-34a and FXR projects in my thesis reveal new potential targets for both diagnosis 
and treatment of metabolic diseases.         
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Chapter One 
Background and Significance 
1. Introduction 
1.1 Metabolic Homeostasis, Energy Balance and Obesity 
1.1.1 Obesity is a disease! 
Being overweight or obese is one of the first stage of metabolic disorder in humans. During 
ancient times, humans faced food scarcity, malnutrition, war, and diseases. Thus people tend to 
want to eat more and store energy, in order to survive in these “hunger games”. However, these 
thrifty genes inherited from our ancestors keep us overeating and result in excess weight and 
obesity (1).  
An escalating global epidemic of overweight and obese people has been termed “globesity” 
(4). In the past three decades, the number of overweight and obese people worldwide has reached 
2.1 billion in 2013, with 37% men and 38% women considered obese or overweight (1-3). The 
United States has the highest rate of obesity. One third of its adult population is obese, and about 
two thirds are overweight. Moreover, childhood obesity has increased at an alarmingly rate. 
According to the Centers for Disease Control and Prevention (CDC), childhood obesity has more 
than doubled in children and quadrupled in adolescents since 1980. In 2012, more than one third 
of children and adolescents were overweight or obese and they tended to developed obesity-
related metabolic diseases at an even earlier age than in the past. Obesity now is an issue 
affecting people from all ages and incomes and everywhere. The American Medical Association 
(nation’s leading physician’s organization) recently characterized obesity as a “disease” and 
declared war against it. Obesity increases the risk of metabolic related diseases, including type 2 
 2 
diabetes, cardiovascular disease, fatty liver diseases, hypertension and stroke, and other human 
diseases like female infertility, mental depression and even certain types of cancer (4-6). 
      
1.1.2 Energy Balance and Metabolic Homeostasis 
Obesity, characterized by excessive body weight, is often considered to result from an 
imbalance between energy intake and energy output. Either excessive food intake or insufficient 
physical activity can cause energy imbalance. The food we take in and the energy generated from 
it has three common fates. It is either stored as ATP for mechanical work or chemical synthesis 
used for the body, or stored as fat, or immediately dissipated as heat. The overload of stored fat 
in obesity disrupts normal metabolic homeostasis resulting in abnormally elevated cholesterol, 
lipid and glucose levels and eventually metabolic diseases. Therefore, regulation of cholesterol, 
lipid and glucose levels in the body are critical for maintaining the metabolic homeostasis and 
good health. 
 
1.1.3 Metabolic regulators 
The common mechanism for metabolic regulation in complex organisms relies on three 
types of control. The first is the regulation of the activity of a key enzyme in the metabolic 
pathway, which may triggered by the binding of an activator. The second involves post-
transcriptional modification (PTM) of those key enzymes, such as proteolytic cleavage, 
phosphorylation, acetylation, etc. to activate or inactivate the enzyme. These two types of control 
are centered on the modulating activity of key enzymes through protein-protein interaction or 
protein modification. So these subsequent changes are relatively rapid and transient, but the third 
kind of control, transcriptional regulation, affects the expression level of key enzymes, key 
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signaling pathway genes, or key hormones is effective on a longer time period.  
To delicately maintain metabolic homeostasis, metabolic transcriptional regulators function 
as sensors for specific signals, and then transduce the signal to the cell nucleus where it targets a 
specific sets of genes. Many such metabolic regulators are members of the nuclear receptor 
superfamily. They function as sensors that are triggered by specific ligands. Then, they function 
as effectors, to transduce the information into the nucleus and act as transcriptional factors to 
target specific downstream genes.   
 
1.2 Function of FXR as a metabolic regulator 
1.2.1 The nuclear receptor superfamily 
Nuclear receptors (NRs) are integrators of hormonal and nutritional signals, mediating 
changes in metabolic pathways within the body. NRs regulate the activity of genetic networks 
involved in several diverse physiological functions including reproduction, development and 
metabolism in response to signaling molecules including steroids, retinoids, fatty acids, and bile 
acids (9). Given that lipid and glucose metabolism has been linked to diseases including type 2 
diabetes, obesity and cardiovascular disease, a greater understanding of pathways that regulate 
metabolism in physiology and in disease states is crucial. Decades of research on nuclear 
receptors indicates that nuclear receptors play an essential role, not only in the regulation of 
cholesterol and bile acid metabolism, but also in the integration of sterol, fatty acid and glucose 
metabolism (10).   
Nuclear receptors are conserved in structure and usually contain 5 domains (11) (Fig. 2). 
The first N-terminal regulatory domain contains activation function 1 (AF-1) whose action is 
independent of the presence of ligand. The second is the DNA-binding domain (DBD), which is 
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a highly conserved domain containing two zinc fingers that binds to specific sequences of DNA 
called hormone response elements (HRE). The third domain is the hinge region. It is a flexible 
domain that connects the DBD with the LBD. It also influences intracellular trafficking and 
subcellular distribution. The fourth domain is the ligand binding domain (LBD), which is 
moderately conserved in sequence and highly conserved in structure between the various nuclear 
receptors. The fifth domain is the C-terminal AF-2 domain whose action is dependent on ligand 
binding (12, 13).  
The NRs can be broadly divided into three groups based on their physiologic ligands and 
potential functions (14). The first class of NRs contains the classic endocrine receptors featuring 
very high affinity for ligands. They are essential for homeostatic regulation of the endocrine 
system, which includes steroid hormone receptors, such as estrogen receptor (ER), androgen 
receptor (AR) and vitamin A and D receptors. The second and third classes of NRs are NRs 
which are identified based on their sequence homology to the endocrine NRs, but lacked a 
known cognate ligand at the time of discovery and were called orphan receptors. Researchers 
used reverse endocrinology which refers to using a receptor to discover its natural ligand rather 
than using a known ligand to identify its receptor. Many endogenous and exogenous compounds 
have been identified as ligands for some orphan NRs, thus these NRs are de-orphanized or called 
adopted. The adopted NRs belong to the second class of NRs, which show low affinity for their 
ligands. This category of NRs is also referred to as metabolic receptors, since they are essential 
in regulating lipid and glucose uptake, synthesis, storage, and clearance, although the function of 
some adopted receptors has not been characterized (11). The third class of NRs contains the 
remaining true orphan NRs, whose ligands have not yet been identified to date.  
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1.2.2 FXR as a nuclear receptor 
 As mentioned above, NRs are transcriptional factors that integrate hormonal, metabolic 
and nutrition signals with gene expression changes. Farnesoid X receptor (FXR) is a member of 
the nuclear receptor superfamily and is classified as NR1H4. It is highly conserved from teleost 
fish to humans suggesting a critical functional role for FXR (15). A single human or mouse gene 
encodes four isoforms of FXR (Fig. 3).  
 FXR is highly expressed in the liver, intestine, kidney and adrenal gland and at much 
lower levels in adipose tissue. In general, NRs bind as monomers or dimers to specific DNA 
sequences termed hormone response elements and regulate gene expression. Like many other 
non-steroid hormone NRs, FXR binds to specific DNA elements called FXR response elements 
(FXRE) as a heterodimeric complex with 9-cis-retinoid X receptor (RXR, NR2B2) (16). The 
FXRE contains two copies of a consensus sequence (AGGTCA) represented as inverted repeats 
separated by one nucleotide (IR1) or everted repeats separated by 8 nucleotides (ER8) or direct 
repeats separated by four nucleotide (DR4) (17, 18).  
 
1.2.3 Role of FXR in maintaining bile acid and cholesterol homeostasis 
 Bile acids have been identified as the endogenous ligands that bind to and activate FXR. 
The order of potency of endogenous bile acids is chenodeoxycholic acid (CDCA) > lithocholic 
acid (LCA) = deoxycholic acid (DCA) > cholic acid (CA). Synthetic FXR-specific agonists, such 
as GW4064, fexaramine, and 6α-ethyl-chenodeoxycholic acid (ECDCA) have been developed. 
The generation of synthetic specific FXR agonists has enabled advanced investigations of FXR 
to understand its functions in controlling diverse metabolic pathways (19).  
 Bile acids not only serve essential dietary roles in the absorption of fat-soluble nutrients, 
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but also function as endocrine signaling molecules that integrate and coordinate metabolic 
regulation and energy balance (20). As the primary biosensor for endogenous bile acids, the FXR 
regulates expression of numerous bile-acid-responsive genes involved in bile acid, cholesterol, 
fat and glucose metabolic pathways (21). FXR is a ligand-activated transcription factor that 
controls the expression of genes responsible for the diverse functions (22). In addition to 
inducing gene expression directly, the FXR/RXR heterodimer indirectly inhibits some target 
genes by induction of an orphan nuclear receptor and transcriptional corepressor, small 
heterodimer partner (SHP) (23). The FXR/SHP pathway has been shown to play a crucial role in 
the negative feedback regulation of bile acid synthesis by inhibiting the bile acid synthetic genes, 
Cyp7a1 and Cyp8b1, and by inhibition of other metabolic genes, such as Pepck, G6pase, Apo-A1, 
and Srebp1-c (sterol-regulatory element-binding protein 1C) (24, 25). In addition as mentioned 
before, FXR promotes the release of FGF19 from intestine which acts on the liver by binding to 
its βKL/FGFR4 receptor complex to reduce CYP7A1 expression and thus repress bile acid 
synthesis (29, 30). In addition to its functions in metabolism, roles for FXR in liver regeneration, 
anti-inflammation, and tumor suppression have been recently demonstrated. 
 Broadly, FXR is viewed as acting in a complementary or reciprocal fashion to liver X 
receptors (LXRs) in the control of lipid metabolism. FXR inhibits whereas LXR promotes bile 
acid production in mice, and the two receptors modulate glucose and lipid metabolism in a 
tissue-specific manner (9, 10). High levels of bile acids are toxic to cells, and thus FXR has a 
crucial role in maintaining control of bile acid levels. Bile acids facilitate the efficient digestion 
and absorption of fats and cholesterol after a meal. In addition, formation of bile acids is a major 
pathway for cholesterol elimination from the body. Most bile acids are recycled via the 
enterohepatic circulation, passing from the intestine back to the liver, thereby reducing the 
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requirement for de novo bile acid synthesis (20).  
 FXR also reduces bile acid toxicity in the liver by increasing other bile acid-modifying 
enzymes including sulphotransferase 2A1 (SULT2A1) and CYP3A4. FXR also promotes the 
transport of bile acids to the gall bladder via bile salt export pump (BSEP), multidrug resistance 
protein 2 (MDR2), and MDR3. Within the intestine, FXR reduces bile acid absorption via down-
regulation of the apical sodium-dependent bile acid transporter (ASBT), promotes bile acid 
movement across the enterocyte via ileal bile acid binding-protein (IBABP) and promotes 
recycling of bile acids to the liver via organic solute transporters (OST), OSTα and OSTβ. In 
addition, FXR reduces hepatic uptake of bile acids by reducing the expression of organic anion 
transporting polypeptide (OATP) and sodium taurocholate cotransporting polypeptide (NTCP) 
(24). 
 
1.2.4 Role of FXR in lipid homeostasis 
FXR plays a crucial role in maintaining lipid homeostasis by regulation of many lipid 
metabolic genes. The activation of FXR by an agonist results in reduced plasma triglycerides, 
hepatic lipogenesis, cholesterol levels, synthesis of free fatty acids (FFAs), and secretion of 
VLDL from liver (26). Increased LDL and induction of genes involved in lipoprotein metabolism 
and clearance by FXR activation is entirely consistent with previous findings in regulation of 
plasma lipids (27, 28). In FXR-deficient mice, serum high-density lipoprotein (HDL), cholesterol, 
and TG levels are elevated, whereas hepatic expression of the HDL receptor scavenge receptor 
class-B1 (SRB1), which facilitates HDL cholesterol removal from the blood, is decreased (15,16). 
In addition, FXR-null mice have higher circulating free fatty acids (FFA) levels than wild-type 
mice fed a high-fat diet, which is attributable to increased lipoprotein lipase activity. Hepatic TG 
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levels are controlled by a balance between fatty acid oxidation and synthesis, with the former 
controlled by PPARα and the latter by SREBP1 (16, 28). FXR activates SREBP1 and its 
lipogenic target genes in mouse primary hepatocytes and liver. FXR also regulates the expression 
of PPARα, a key regulator of lipid metabolism and its target genes. Activated PPARα increases 
fatty acid oxidation, lipolysis, energy uncoupling and expenditure, while decreasing lipogenesis, 
TG secretion and adiposity. FXR regulates lipid metabolism by balancing the expression of these 
two genes.  
 
1.2.5 Role of FXR in glucose homeostasis 
FXR also maintains glucose homeostasis. As mentioned above, FXR promotes the 
release of FGF19 from intestine. FGF19 acts at the liver by binding to its βKL/FGFR4 receptor 
complex and induces downstream Erk signaling to inhibit CYP7A1 expression and thus repress 
bile acid synthesis (29, 30). So in the liver, FXR not only regulates glucose metabolism through 
FGF19 pathway, but also through Shp, which acts by reducing gluconeogenesis via the down-
regulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6Pase), two key enzymes in the glucose synthesis (31). Furthermore, FXR reduces lipogenesis 
via inhibition of SREBP1C and fatty acid synthase (FAS) (32). 
 Both GW4064 and chenodeoxycholic acid (CDCA), which activate FXR, protect 
hepatocytes from cholestasis induced by α-naphthylisothiocyanate and estrogen. In addition, 
activation of FXR in diabetic obese mice by long term treatment of GW4064 improved 
metabolic outcomes by reducing serum glucose and lipid levels. These studies suggest that 
changes in FXR expression and activity may affect numerous genes that are associated with 
metabolic diseases (33). Together, the current data suggest that FXR agonists may be useful in 
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the treatment of type 2 diabetes, hypertriglyceridemia, certain cholestasis conditions (34), and 
cholesterol gallstone disease (35). Although FXR has been shown to be critical for hepatic 
metabolism and activation of FXR improves metabolic outcomes in diet-induced obese mice, it 
is unclear how FXR modulates or regulates target genes for liver metabolism (36).  
 
1.2.6 Other novel function of FXR 
 New functions of FXR are continuously being identified, including its functions as a tumor 
suppressor or as an anti-inflammation. Hepatic ChIP-seq analysis of FXR binding by our group 
revealed other new category of genes to which FXR binds, such as autophagy, which is one of 
the studies focused of one of the studies in this thesis.  
 
1.3 MicroRNAs as key regulators in obesity 
1.3.1 MicroRNAs in obesity 
 MicroRNAs (miRs) are small (approximately 22 nt) non-coding RNAs that regulate gene 
expression at the post-transcriptional level. MiRs bind to the 3’-untranslated region (UTR) of 
target mRNAs and inhibit their expression by causing mRNA instability or by inhibiting 
translation (37). Approximately 30% of all human genes are predicted to be regulated by miRs, a 
recent explosion of research shows that miRs regulate gene expression in diverse biological 
processes including development, differentiation, cell proliferation and apoptosis, cancer, and 
metabolism (38, 39). A number of the miRs are involved in lipid and glucose metabolism in 
major metabolic tissues such as liver, pancreas, adipose, and muscle (40, 41).
 
Among all miRs 
involved in liver diseases, miR-34a is a shining star (42).
 
Clinical studies demonstrated that in 
patients with NASH (non-alcoholic steatohepatitis), miR-34a levels were increased ~100 times, 
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compared to healthy people.
 
MiR-34a levels are also increased more than 6-fold in patients with 
NAFLD (non-alcoholic fatty liver disease) and with chronic hepatitis C (43).
 
MiRNA microarray 
studies performed in different labs also reported that the level of miR-34a increased ~10-fold in 
leptin-deficiency ob/ob mice and diet-induced obese (DIO) mice (44); and increased ~ 6-fold in 
STZ-induced diabetic mice (44). MiR-34a almost always tops the list of miRs with changed 
expression profiles in these microarrays carried out in clinical liver diseases and obese mice.  
 
1.3.2 MicroRNAs as metabolic regulator 
Crucial roles of miRNAs in the regulation of cellular metabolism have been investigated 
intensively in recent years. The most abundant miRNA in liver, miR-122 plays important roles in 
a wide variety of liver functions ranging from cholesterol metabolism, liver cancer, stress 
responses, and viral infection to circadian regulation of hepatic genes (45). MiR-33 has been 
shown to contribute to the regulation of cholesterol homeostasis by targeting the cholesterol 
transporter genes, ABCA1 and ABCG1 (46, 47). MiR-34a was also shown to have a role in 
glucose metabolism by suppressing insulin secretion in pancreatic β-cells (48). The roles of miR-
375 in pancreatic islet functions, especially in insulin gene transcription, insulin secretion, and 
islet cell growth, have been also well established (49). Many miRs are found to regulate glucose 
metabolism and insulin sensitivity, including let-7 (50), miR-802 (51), miR-103 or miR-107 (44), 
and miR-143 or miR-145 (52). For lipid metabolism, miR-27 (53) and miR-378 (54) were 
reported to control adipocyte differentiation and lipid synthesis, respectively (55). In heart, miR-
223 (56) was shown to regulate glucose uptake in cardiomyocytes, and miR-696 was shown to 
regulate mitochondria biogenesis and fatty acid oxidation in gastrocnemius muscle (57). In line 
with their critical functions, miRNAs are often underexpressed or overexpressed in disease states 
(58). Recent studies have shown that restoring miRNAs or downregulating miRNAs using 
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antisense miRNA inhibitors, called Antagomirs (59), may result in improved transcriptional and 
biological outcomes, demonstrating that miRNAs are promising therapeutic targets. 
 
1.3.3 Therapeutic potential of miR inhibitors 
Currently it is estimated that only 1% of the genomic transcripts in mammalian cells 
encode miRs, where as nearly one-third of the encoded genes are regulated by miRs. Moreover, 
the recent employment of miR inhibitors has shown that miRs of interest can be specifically 
targeted. In addition, recent studies have shown that downregulation of aberrantly elevated miR-
103/miR-107 in obesity improved insulin sensitivity. Antagonism of microRNA-122 in mice by 
systemically administered LNA conjugated antisense miRNA resulted in up-regulation of a large 
set of predicted target mRNAs in the liver (45).
 
Antagonism of miR-33 promoted cholesterol 
transport and showed beneficial effects on atherosclerosis (47, 60).
 
In another study, inhibition of 
miR-33a/b in non-human primates raised plasma HDL and lowered VLDL (46). All these recent 
in vivo antagonism studies of miRNA illustrate the potential of in vivo antisense microRNA as 
therapeutic treatments. There are several options for antisense approaches, including antagomiRs, 
which are conjugated to cholesterol to facilitate cellular uptake; locked nucleic acid (LNA) 
phosphorothioate chemistry; or chemical modification of the oligonucleotide at 2’-sugar and 
phosphate backbone moiety with MOE (2’-O-methoxyethylphosphorothioate) (61, 62). 
 
1.4 Endocrine fibroblast growth factors, FGF19 and FGF21 
Fibroblast growth factors, FGF19 and FGF21 can function as peptide endocrine 
hormones. Both of them act on multiple tissues to coordinate glucose and lipid metabolism in 
response to delicate nutrient dynamics in vivo (Fig. 5). In the healthy state, FGF19 is secreted 
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from the small intestine after feeding and has actions similar to insulin, whereas FGF21 is 
synthesized in the liver in response to prolonged fasting and has effects similar to glucagon (63).  
 
1.4.1 Function of FGF19 in metabolism 
 Most FGFs are highly conserved and act in an autocrine or paracrine fashion, FGF19 and 
its rodent ortholog FGF15, function as endocrine hormones (64). They can be released into the 
blood stream to act throughout the body, reaching the proximal organ which expresses their 
receptor complex. Initially, various functions of FGF19 were reported in neurons and cancer 
development, including suppression of proliferation and promotion of differentiation.
  
However, a primary function of FGF19 in the adult is to regulate bile acid homeostasis.
 
Bile acids are amphipathic molecules that are released postprandially from the gallbladder into 
the small intestine, where they play an essential role in the solubilization of dietary lipids. About 
95% of bile acids are reabsorbed in the ileum and returned to the liver and gallbladder via the 
hepatic portal vein.
 
Accumulation of bile acids in the liver can have toxic effects. Therefore, the 
intracellular levels of bile acids must be tightly regulated, which is accomplished by the 
transcriptional and post-translational regulation of proteins involved in bile acids synthesis, 
transport and metabolism. The master regulator among the transcriptional regulators of bile acids 
homeostasis is FXR. FXR, activated by bile acid binding, plays important roles in the regulation 
of glucose metabolism, lipid metabolism, and inflammation. So taken together, in the feeding 
state, bile acids are released in the intestine and bind to FXR. The bile acid-bound FXR forms a 
heterodimer with RXR and functions as a transcription factor that increases expression of FGF19 
in intestinal epithelial cells. Secreted FGF19 travels through the enterohepatic circulation and 
activates its receptor complex in hepatocytes in livers. Fibroblast growth factor receptor-4 
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(FGFR4) forms a complex with its co-receptor beta-klotho (βKL) on the membrane of 
hepatocytes. The activated FGF19 signaling initiates a series of downstream signaling cascades 
and suppress the expression of Cyp7A1 gene, which encodes the rate-limiting enzyme for bile 
acid synthesis. Thus, FGF19 reduces bile acid synthesis in liver. This intestine-liver endocrine 
axis mediated by FGF19 and βKL is indispensable for maintaining bile acid homeostasis, 
because mice lacking either FGF15, βKL, or FGFR4 exhibit increased Cyp7a1 expression, 
increased hepatic bile acid synthesis and excretion, and smaller gallbladders.  
Besides decreased bile acid synthesis and gallbladder filling, another important 
downstream effect of FGF19 signaling is to increase protein and glycogen synthesis and decrease 
gluconeogenesis (Fig. 4). FGF19 signaling induces protein synthesis through activation of the 
Ras/Raf/Mek/Erk/Rsk pathway that activates translation factors S6 and elF4B. It stimulates 
glycogen synthase (GS) activity and glycogen synthesis through inactivation of GSK (glycogen 
synthase kinase) (65). It represses gluconeogenesis by blocking the phosphorylation and 
activation of CREB (cAMP response element-binding protein), a transcriptional factor that 
induces PGC1-α (peroxisome proliferator-activated receptor γ coactivator1-α) expression (66).  
Several studies from other groups and as well my work also show that FGF19 has a role 
in controlling energy homeostasis. In mice injected with FGF19 adiposity was reduced and 
hepatic lipid oxidation was enhanced (29). Transgenic mice expressing FGF19 were also been 
protected from diet-induced obesity and had lower serum glucose, insulin, cholesterol and 
triglyceride levels. Although the detailed mechanism has not been elucidated to date, my 
research (see chapter 2) indicates that FGF19 increases glycogen synthesis in the liver, resulting 
in less glucose stored as fat. On the other hand, FGF19 appears to induce glycogen storage, 
hepatic fatty acid oxidation as well (31, 67). 
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 As a fed-state hormone, the FGF19 has very similar effects as insulin, but there are 
important differences between the two. FGF19 mainly triggers Erk signaling pathways, whereas 
insulin mainly acts through Akt signaling. Thus, they elicit different downstream target gene 
cascades. For example, FGF19, unlike insulin, does not stimulate lipogenesis, which is also an 
advantage in considering the FGF19 signaling pathway as a target for anti-diabetic therapy. In 
addition, FGF19 function at different times after a meal compared to insulin. After a meal, 
insulin is released in 5-10 min, will FGF19 induction requires around 30 min. Thus, FGF19 acts 
after insulin in the transition from the fasted to the fed state (63). 
 
 
1.4.2 FGF21 function in metabolism   
 Another important FGF family member that function as a peptide hormone is FGF21. 
FGF21 is mainly expressed in liver, muscle, pancreas and adipose tissue, with the circulating 
FGF21 mainly coming from the liver (68). Among the three FGF hormones, FGF21 is 
particularly interesting due to its special endocrine actions that endow it with potential 
therapeutic uses (69, 70). 
 FGF21 was initially considered to be a starving hormone, since its production is induced 
in mice liver by starvation. In addition, its actions, like inducing gluconeogenesis, fat oxidation, 
and ketogenesis, coupled to a state of torpor, all mimic the effects of fasting (71). Fasting-
mediated induction of FGF21 requires PPARα (peroxisome proliferator-activator receptor α (69)), 
a nuclear receptor activated by fatty acids and the fibrate class of hypolipidemic drugs. PPARα 
directly targets the FGF21 gene to induce its transcription (72, 73). Secreted FGF21 acts as an 
endocrine hormone to induce ketogenesis, gluconeogenesis, and torpor and to inhibit somatic 
growth. FGF21 is also strongly induced in the mouse liver by a high-fat, low-carbohydrate 
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“ketogenic” diet and by suckling in mouse neonates, conditions which mimic starvation in 
forcing the body to burn more fatty acids rather than carbohydrates (74).  
 Besides its response to prolonged fasting, more intriguingly, FGF21 is also responsive to 
feeding or to thiazolidinedione drugs (TZDs) (75) . FGF21 expression is induced by PPARγ 
(peroxisome proliferator-activator receptor γ) in adipose tissue, where FGF21 acts through a 
positive feedback autocrine mechanism to stimulate PPARγ activity (68, 76). Secreted FGF21 
binds mainly to FGFR1/βKL complexes in hepatocytes or adipocytes and stimulates Erk 
signaling resulting in modulation of gene expression by reducing levels of the lipogenic 
transcription factor SREBP1 in the liver and inducing expression of the metabolic co-activator 
protein PGC-1α in the liver and adipose tissue (77). FGF21 also induced glucose transporter-1 
(GLUT1) and promoted glucose uptake in murine 3T3-L1 and human primary adipocytes (78). 
FGF21 administration to the obese mice resulted in decreased hepatic triglycerides, decreased 
plasma triglyceride and glucose levels, and caused weight loss by increasing energy expenditure 
and reducing fat mass (79). Clinical study also showed that FGF21 treatment of obese patients 
has similar effects, such as weight loss, lowering serum free fatty acid and triglyceride levels, 
and improved glucose tolerance. In both mice and humans, FGF21 appears to have potent 
insulin-sensitizing actions. Surprisingly, however, FGF21 levels are elevated in obese mice and 
correlate positively with BMI value in humans (80) suggesting that obesity may be a FGF21-
resistant state.  
 Collectively, imbalance in energy metabolism happens at two extremes, prolonged fasting 
and the obese state (70, 81, 82). Either situation will induce FGF21 expression level, in order to 
accelerate the energy burning process. However, some studies showed that FGF21 cannot 
activate its downstream signaling in obesity, which suggested that obesity is a FGF21-resistant 
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state (83). My second project is about how levels of the FGF21 receptor complex are reduced in 
obesity so that FGF21 signaling is impaired. 
 
1.4.3 Essential role of βKL in FGF19 and FGF21 signaling 
As mentioned before, βKL is a co-receptor on the cell membrane for FGF19 and FGF21 
(84). The effect of βKL on energy metabolism, aging and cancer is a fascinating and recent, still 
unfolding story. βKL is a single-pass type 3 membrane protein. βKL interacts with FGFR4 
mainly in liver to receive FGF19 signaling (65); it also can interact with FGFR1 in the adipose 
tissue to receive FGF21 signaling (85). FGFRs are tyrosine receptors that initiate and transduce 
the signaling to downstream effectors, but they are broadly present in every tissue. However, 
their co-receptor, βKL plays a more important physiological role, due to its limited tissue 
distribution. βKL is mainly present in liver, adipose tissue, pancreas and at lower levels in 
muscle and intestine. βKL-null mice are viable and fertile, but have an altered bile acid 
metabolism: they have increased Cyp7a1 levels, secrete more bile acids and are resistant to 
cholesterol gallstone formation. Since βKL, functions as a co-receptor, mediates both FGF19 and 
FGF21 signaling, the factors which can affect βKL expression level are significantly important 
(86).  
 
1.5 Conclusion 
There has been an upsurge of interest in study nuclear receptors and miRNAs as 
metabolic regulators. The nuclear receptor function as a sensor and effector for cellular signaling 
receiving and transducing in cytoplasm, then play a role of transcriptional regulator, targeting 
specific downstream genes in the nucleus. MiRNA works as a post-transcriptional regulator, 
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sometimes targeting multiple genes in same functional pathway. Moreover, some NRs interplays 
with miRs on different levels of regulation. In this thesis, I elucidated the critical importance and 
interplay among FXR, miR-34a and FGFs. There are four studies described in the following 
chapters, illustrating their roles in different metabolic settings, fasting and feeding, normal 
physiological and pathophysiological conditions. 
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Chapter Two 
    Elevated miR-34a in obesity attenuates hepatic responses to 
FGF19 signaling 
1. Abstract 
 MicroRNA-34a (miR-34a) is the most highly elevated hepatic miR in obese mice and 
also substantially elevated in patients with steatosis and but its role in obesity and metabolic 
dysfunction remains unclear. After a meal, fibroblast growth factor 19 (FGF19) is secreted from 
the ileum, binds to a hepatic membrane receptor complex, FGF receptor 4 (FGFR4) and 
coreceptor beta-Klotho (βKL), and mediates postprandial responses under physiological 
conditions, but hepatic responses to FGF19 signaling were shown to be impaired in steatosis 
patients. Here I show an unexpected functional link between aberrantly elevated miR-34a and 
impaired βKL/FGF19 signaling in obesity. In vitro studies show that miR-34a downregulates 
βKL by binding to the 3’ untranslated region of βKL mRNA. Adenoviral-mediated 
overexpression of miR-34a in mice decreased hepatic βKL levels, impaired FGF19-activated Erk 
and Gsk signaling, and altered expression of FGF19 metabolic target genes. Consistent with 
these results, βKL levels were decreased and hepatic responses to FGF19 were severely impaired 
in dietary obese mice that have elevated miR-34a. Remarkably, in vivo antisense inhibition of 
miR-34a in obese mice partially restored βKL levels and improved FGF19 target gene 
expression and metabolic outcomes including decreased liver fat.   
 
 
This chapter appeared in its entirety in the Proc. Natl. Acad. Sci. U. S. A. and cited later in this 
dissertation as Fu, T. et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic 
responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc. Natl. Acad. Sci. U. 
S. A. 109, 16137-16142 (2012). 
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Further, anti-miR-34a treatment in primary hepatocytes of obese mice restored FGF19-activated 
ERK and GSK signaling, in a βKL-dependent manner. These results indicate that aberrantly 
elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL. The 
miR-34a/βKL/FGF19 axis may present novel therapeutic targets for FGF19-related human 
diseases, including metabolic disorders and cancer. 
 
2. Introduction 
 Metabolic disorders, such as fatty liver, obesity, and type II diabetes, due to abnormally 
regulated lipid and glucose levels are serious medical problems worldwide (1). The roles of 
pancreatic insulin in the regulation of fed-state metabolism and development of such metabolic 
disorders are well known, but recently discovered and relatively less understood is the role of an 
intestinal hormone, fibroblast growth factor 19 (human FGF19, or mouse FGF15) (2). FGF19 
constitutes a novel endocrine metabolic regulatory axis.  After a meal, expression of FGF19 is 
induced by the bile acid-activated nuclear receptor, Farnesoid X Receptor (FXR), in the small 
intestine (2). Secreted FGF19 binds to a hepatic membrane receptor complex, FGF receptor 4 
(FGFR4) and its coreceptor β-Klotho (βKL) (3-6), and triggers the activation of cellular kinases 
including ERK and GSK to mediate post-prandial metabolic responses (7, 8). Interestingly, a 
recent study showed that the hepatic response to FGF19 is impaired in patients with nonalcoholic 
fatty liver disease (NAFLD) and insulin resistance (9). Despite the functional importance of βKL 
in transmitting FGF19 signaling, little is known about how the expression of βKL is regulated 
and why FGF19 signaling is impaired in fatty liver patients.  
 MicroRNAs (miRs) are small non-coding RNAs and function as negative gene regulators 
(10). MiRs directly bind to the 3’ untranslated region (UTR) of target mRNAs and inhibit 
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translation and/or destabilize target mRNAs (11). Consistent with their critical biological 
functions, miRs are aberrantly expressed in human diseases, such as, metabolic disease and 
cancer (10, 12). Our lab previously shown that miR-34a which targets SIRT1 deacetylase is 
aberrantly elevated in fatty livers of high fat diet-induced obese mice and leptin-deficient ob/ob 
mice and that miR-34a is the most highly elevated hepatic miR in metabolic disease-prone FXR-
null mice (13, 14). Consistent with these findings, a recent study has shown that miR-34a was 
the most highly elevated hepatic miR in dietary and genetic obese mice (15). Importantly, 
hepatic miR-34a levels are substantially elevated in NAFLD and type 2 diabetic patients (16-19). 
However, the role of miR-34a in obesity and metabolic dysfunction remains unclear.  
 Here, I present evidence demonstrating a surprising functional link between aberrantly 
elevated miR-34a and impaired βKL/FGF19 signaling in obesity. I further present the exciting 
therapeutic possibility of using in vivo antisense inhibition of elevated hepatic miR-34a for 
treating metabolic disorders.  
 
3. Materials and Methods 
3.1 Reagents and materials  
 Antisense-miR-34a and q-RTPCR primers for miR-34a were purchased from Applied 
Biosystems. The siRNA for βKL was purchased from Ambion. βKL antibodies for western 
blotting and IHC were purchased from R&D systems (AF2619) and Life Span Biosciences (LS-
B3568), respectively. Antibodies to lamin (sc-20680), tubulin (sc-8085), and FGFR4 (sc-136988) 
were purchased from Santa Cruz Biotech and antibodies for p-ERK (#9101), t-ERK (#4695), p-
AKT (#9271), t-AKT (#9272), p-GSK (#9327), and t-GSK (#5676) were purchased from Cell 
Signaling.   
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3.2 Animal experiments  
 Six week-old male Balb/c mice were fed normal chow or high fat chow (60% fat) for 14-
20 weeks. Control Ad-empty or Ad-miR-34a, at a dose of 0.1-1.0x10
9
 active viral particles in 
100 ml PBS, were injected via the tail vein of mice as previously described (27, 28, 34, 35).  
Adenoviral vectors are useful for hepatic studies because adenoviral-mediated expression of 
proteins, miRs, and siRNA is largely confined to the liver (36). In vivo anti-miR-34a 
experiments were performed as in the previous miR-122 studies in liver (37). All animal use and 
adenoviral/anti-miR-34a protocols were approved by the Institutional Animal Care and Use and 
Institutional Biosafety Committees at University of Illinois at Urbana-Champaign and were in 
accordance with National Institutes of Health guidelines.  
 
3.3 Construction of βKL 3’UTR-luc reporter  
 A SpeI/ HindIII fragment containing the 3’UTR of βKL was inserted into the pMIR 
plasmid (Invitrogen), named WT. Mutations in the 3’UTR were made by using site-directed 
mutagenesis (Stratagene). The mutated 3’UTR fragment was also inserted into pMIR plasmid, 
named Mut. Positive clones were identified by DNA sequencing.  
 
3.4 Transfection reporter assay  
 Hepa1c1c7 cells were used for up-regulation of miR-34a because they have relatively 
low levels of miR-34a, whereas Cos-1 cells, which have high levels of miR-34a, were used for 
downregulation of miR-34a. Cells were transfected using Lipofectamine (Invitrogen) and 
Luciferase reporter assays were performed as described before (27, 28, 34, 35). Basically, cells 
were co-transfected with Luciferase vector pMIR (WT or Mut) one, plasmid containing β-gal as 
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an internal control for transfection efficiency. After luciferase plasmid expressed in 24-36 h, I 
transfected with anti-miRNA or siRNA of target genes. After another 24-48 h, I checked out the 
β-gal activity and luciferase activity. Anti-miR-34a (Ambion®) which is complementary to 
mature miR-34a sequences was used for down regulation of mature miRNA and anti-N-control 
(Ambion®) that has a random sequence was used as a control. The anti-miRNAs were modified 
and are not easily degraded in cells. 50 to 200 nM of anti-miRNAs was transfected with 2-3 μl of 
Lipofectamine 2000 (Invitrogen) in serum free media for 24-48 h and miRNA levels were 
analyzed by q-RTPCR. SiRNA designed to knocking down target gene expression levels by 
complementary to the mRNA sequence of the target genes were pre-designed on Ambion 
website. 5 nM of the siRNAs were transfected with 2-3µl Lipofectamine 2000 (Invitrogen) in 
serum free media for 24-36 h and siRNA knockdown efficiency was tested. 
 
3.5 q-RTPCR analysis  
 Total RNA was isolated by Trizol reagent (Invitrogen). The mRNAs were reverse-
transcribed to cDNA (Progema) and q-RT-PCR was carried out with SYBR reagent (Roche). 
Target gene expression levels were normalized with 36B4 as internal control gene. Primer 
sequences are available in the Supplemental Information (Fig. S15). miRNA were reverse-
transcribed using specific RT primers (Applied Bioscience) and the expression levels were 
checked by Taqman q-RT-PCR method, a set of two primers and one probe were purchased from 
Applied Bioscience as well. Basically, for the RT and q-RT-PCR of miRNAs, total liver RNA (5 
µg) was isolated, reverse transcription (RT) reaction at 16°C for 30 min and 42°C for 30 min 
followed by 85°C for 5 min using the Taqman® RT-reaction Kit with Taqman® miR-34a 
specific primers (Applied Biosystem). Quantitative-PCR was carried out at 95°C for 15 sec 
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(denature) and 60°C for 1 min (anneal/extend) for a total of 40 cycles using ABI7900 (Applied 
Biosystem). Quantification of expressed miR-34a was normalized with SnoRNA202 (Applied 
Biosystem).   
 
3.6 Western blot and co-Immunoprecipitation (CoIP) assays 
 IP assays were performed as previously described (Kemper et al., 2004). Briefly, cell 
extracts and mouse liver nuclear extracts were incubated in buffer (20 mM-HEPES, pH 7.9, 1 
mM EDTA, 10% glycerol, 150 mM NaCl, 0.5% NP40, and protease inhibitors) with antibodies 
at 4
o 
C for 4 h to overnight and the immune complex was collected by incubation with protein G 
sepharose for 2 h. Immunoprecipitates were washed four times with lysis buffer with 300 mM 
NaCl and subjected to western blotting. 
 
3.7 Isolating the primary mouse hepatocytes (PMH)  
 Hepatocytes were isolated by collagenase (0.8mg/ml, Sigma-Aldrich Co.) perfusion 
through the portal vein of mice anesthetized with isoflurane. The hepatocyte suspension was 
filtered through a cell strainer (100 µm nylon, BD), washed with M199 medium (M4530, Sigma), 
resuspended in M199 medium, and centrifuged through 45% Percoll (Sigma-Aldrich Co.). The 
obtained pellets contain viable hepatocytes and all resuspended into experimental cell plate.   
 
3.8 FGF19 signaling experiments in PMH 
 Hepatocytes were transfected with 100 nM of anti-miR-34a or control RNA using 
Lipofectamine. Thirty six to forty eight hours later, hepatocytes were further transfected with 
siRNA for βKL or control siRNA (5 nmoles), and then, 36-48 h later, incubated with serum-free 
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media for 3 h and then further treated with FGF19 (100 ng/ml) for 15-30 min and harvested for 
further analyses.  
 
4. Results 
4.1 MiR-34a and βKL levels are inversely correlated  
 The 3’UTRs of mouse and human βKL mRNAs contain imperfect complementary 
nucleotide sequences to the miR-34a seed sequence (Appendix, Fig. A1). Downregulation of 
miR-34a by antisense miR-34a in mouse Hepa1c1c7 cells resulted in a dose-dependent increase 
in expression of βKL, as well as a known miR-34a target, SIRT1 (14, 20) (Fig. 6A-D, Appendix, 
Fig. A2). Conversely, overexpression of miR-34a resulted in decreased βKL protein levels (Fig. 
6E-F, Appendix, Fig. A3). In mouse liver in vivo, adenoviral-mediated overexpression of miR-
34a resulted in substantial decreases in βKL protein levels (Fig. 6G, H). These results indicate 
that miR-34a and βKL levels are inversely correlated, suggesting that miR-34a may target βKL.  
 
4.2 MiR-34a directly targets βKL 
 To examine whether miR-34a directly targets the βKL 3’UTR, the wild type or a mutated 
miR-34a binding site in the βKL 3’UTR was inserted into a luciferase reporter (Fig. 7A).  
Downregulation of miR-34a with anti-miR-34a increased luciferase activity in a dose-dependent 
manner in Hep1c1c7 cells transfected with the wild type luciferase βKL reporter, but not with the 
mutated βKL reporter or with the control miR oligonucleotide (Fig. 7B-D). Conversely, 
overexpression of miR-34a inhibited the luciferase activity of the wild type βKL reporter in a 
dose-dependent manner but not that of the mutant βKL reporter (Fig. 7E-G). These results 
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indicate that miR-34a negatively regulates βKL and that the inhibition is likely mediated by 
direct binding of miR-34a to the 3’UTR of βKL mRNA.   
 
4.3 Hepatic overexpression of miR-34a impairs FGF19 signaling in vivo 
 FGF19 triggers activation of ERK and GSK in hepatocytes and regulates post-prandial 
responses (3, 4, 6, 7). Since my in vitro studies suggest that miR-34a targets βKL, the coreceptor 
for FGF19 (Fig. 6, 7), I examined whether overexpression of hepatic miR-34a would 
downregulate βKL and affect expression of FGF19 metabolic target genes. Adenoviral-mediated 
hepatic overexpression of miR-34a in mice significantly decreased expression of βKL, as well as 
a known miR-34a target, SIRT1 (14, 20) (Fig. 8A-C, Appendix, Fig. A4). Expression of a well-
known FGF19 downstream target, c-Fos (3, 4) was also decreased whereas expression of the 
hepatic FGF receptor, FGFR4, was not significantly altered (Fig. 8C). Consistent with the 
metabolic action of FGF19 (7, 21), mRNA levels of neutral bile acid biosynthetic genes, Cyp7a1 
and Cyp8b1, (Fig. 8D) and of a gluconeogenic gene, Pepck, were substantially elevated while 
that of G-6-pase was slightly, but not significantly, increased (Fig. 8F). In contrast, mRNAs of 
acidic bile acid synthetic genes, Cyp27a1 and Cyp7b1, were decreased as were those of fatty 
acid oxidation genes, Cpt and Mcad, the bile acid transporter genes, Mrp2, Mrp3, Bsep, and Ntcp 
(Fig. 8D-G, Appendix, Fig. A4). These results indicate that hepatic overexpression of miR-34a 
leads to decreased βKL levels, resulting in altered expression of FGF19 metabolic target genes.   
 To define the effect of miR-34a on FGF19 signaling in vivo, mice overexpressing miR-
34a were treated with PBS or FGF19. Treatment with FGF19 resulted in increased levels of 
phosphorylated Erk and Gsk in mice injected with Ad-empty virus, but little increase was 
observed in mice overexpressing miR-34a (Fig. 8H, I). Similar effects were observed in primary 
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mouse hepatocytes (Appendix, Fig. A5). These results suggest that elevated hepatic miR-34a is 
associated with impaired βKL/FGF19 signaling in vivo.  
 
4.4 Abnormal miR-34a/βKL axis in obesity correlates with impaired FGF19 signaling 
 Hepatic miR-34a levels are substantially elevated in human fatty liver patients (16, 17) 
and obese mice (14, 15). Moreover, hepatic responses to FGF19 are impaired in patients with 
fatty liver disease (9). Therefore, to test if aberrantly elevated miR-34a in obesity correlates 
inversely with βKL levels, I determined the miR-34a and βKL levels in two mouse models of 
obesity. Mice fed a high fat (HF) chow for 16 weeks showed marked fat accumulation in the 
liver (Appendix, Fig. A6) while hepatic miR-34a levels were increased and the expression of 
βKL and FGFR4 were significantly decreased (Fig. 9A-C). Similarly, decreased hepatic βKL 
protein levels and increased miR-34a levels were observed in the leptin gene-deficient ob/ob 
mice (Appendix, Fig. A7). In vivo treatment of normal mice with FGF19 resulted in a substantial 
increase in phosphorylated ERK, but not in phosphorylated AKT, levels (Fig. 9D, Appendix, 
Fig. A8). In contrast, FGF19 had little effect on phosphorylated ERK levels in dietary obese 
mice (Fig. 9D), suggesting that FGF19 signaling is impaired in obese mice. These results suggest 
that an abnormal miR-34a/βKL pathway in obesity contributes to impaired FGF19 signaling.   
 To directly define the role of elevated miR-34a in impaired FGF19 signaling, I examined 
the effects of antisense inhibition of miR-34a on FGF19 signaling in primary hepatocytes. Anti-
miR-34a treatment decreased miR-34a levels and increased βKL mRNA as expected (Fig. 9E, 
F). Consistent with the role of βKL as a coreceptor for FGF19, when βKL was downregulated, 
FGF19 treatment, even at super-physiological doses, did not activate FGF19 signaling 
(Appendix, Fig. A9). In FGF19 signaling experiments, FGF19-mediated ERK and GSK 
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activation was impaired in obese mice but anti-miR-34a treatment restored the ERK and GSK 
activation similar to that observed in normal mice (Fig. 9G, H, Appendix, Fig. A10). These 
results suggest that elevated hepatic miR-34a plays a causative role in impaired FGF19 signaling 
in obesity.  
 
4.5 In vivo antisense inhibition of miR-34a restores expression of βKL and FGF19 
metabolic target genes  
Since impaired βKL/FGF19 signaling in hepatocytes from obese mice result from the 
aberrantly elevated miR34a levels (Fig. 9), I tested whether the defective FGF19 signaling in the 
obesity might be improved by downregulating the miR-34a by injecting with antisense-miR-34a 
(Fig. 10A). Levels of miR-34a were markedly increased and βKL and Fos expression was 
decreased in mice fed HF chow (Fig. 10B, C). Treatment of obese mice with anti-miR-34a 
partially but significantly reduced miR-34a levels toward to those in normal mice (Fig. 10B) and 
significantly restored expression of both βKL and a known miR-34a target, SIRT1 (14, 20) (Fig. 
10B-D, Appendix, Fig. A11). In addition, expression of metabolic target genes involved in bile 
acid, glucose, and fat metabolism were altered in mice fed HF chow (Fig. 10E). The changes in 
expression of these genes were significantly reversed in mice treated with anti-miR-34a (Fig. 
10E, Appendix, Fig. A11). Notably, the responses of these genes to antisense-miR-34a in obese 
mice were the opposite of the effects of overexpression of miR-34a in normal mice (Fig. 8D-G). 
I also examined the effect of anti-miR-34a on βKL and FGFR4 protein levels and their 
membrane localization. Expression of βKL and FGFR4 was dramatically decreased in obese 
mice and anti-miR-34a treatment markedly, although partially, restored their expression levels 
and membrane localization (Fig. 10F). Liver fat levels were decreased, glycogen levels were 
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partially restored, and insulin sensitivity was improved by anti-miR-34a treatment of obese mice 
(Fig. 10G, H).  
 
4.6 βKL is important for improved FGF19 signaling by anti-miR-34a in obesity.  
 To determine whether restored βKL levels are important for improved FGF19 signaling 
by anti-miR-34a treatment in obesity (Fig. 9-10), I examined FGF19 signaling in primary 
hepatocyte of obese mice in which miR-34a and βKL levels were downregulated by anti-miR-
34a and siRNA, respectively (Fig. 10I). In control experiments, transfection with siRNA for βKL 
substantially decreased endogenous βKL levels, which resulted in impaired ERK signaling in 
hepatocytes from normal mice (Fig. 10J, K). FGF19 treatment increased phosphorylation of 
ERK in hepatocytes from normal mice, while little increase was observed in hepatocytes of 
obese mice (Fig. 10L, Appendix, Fig. A12). Anti-miR-34a treatment in hepatocytes of obese 
mice restored the FGF19-mediated ERK- or GSK-phosphorylation (Fig. 10L, M, lanes, 5, 6) and 
this improved FGF19 response was largely blocked by downregulation of βKL (Fig. 10L, M, 
lanes 9, 10, Appendix, Fig. A13). These results indicate that aberrantly elevated hepatic miR-34a 
in obesity impairs FGF19 signaling largely by inhibiting expression of βKL, which contributes to 
resistance to hepatic FGF19 signaling in obesity.  
 
5. Discussion 
In this paper, I show that miR-34a directly targets βKL by binding to the 3’UTR of βKL 
mRNA. This miR-34a/βKL regulatory axis is abnormal in obese mice, which contributes to 
impaired hepatic responses to FGF19. In vivo antisense inhibition of hepatic miR-34a in obese 
mice improved metabolic gene expression and metabolic outcomes. Further, anti-miR-34a 
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treatment in primary hepatocytes of obese mice restored FGF19-activated ERK and GSK 
signaling, in a βKL-dependent manner.   
I have shown that hepatic miR-34a levels were highly elevated in fatty livers of dietary 
and genetic obese mice and exhibited the greatest fold-increase in FXR-null mice compared to 
wild type mice (14, 15). Consistent with my initial findings, miR-34a was recently shown in a 
microarray study to be the most highly elevated miR in fatty livers of HF dietary and genetic 
ob/ob mice (15). Importantly, miR-34a levels are aberrantly elevated in human NAFLD and type 
2 diabetic patients (16-19). All of these recent findings indicate that there is a strong link 
between elevated hepatic miR-34a levels and metabolic abnormalities in liver. However, it was 
not clear whether miR-34a was a cause or consequence of the metabolic abnormalities in obesity.  
My studies provide evidence that abnormally elevated miR-34a in obesity plays a causative role 
in metabolic dysregulation, at least in part, by targeting hepatic βKL/FGF19 axis.  
FGF19 plays an important role in the late fed-state metabolic responses (7, 8, 22).  
Binding of FGF19 to the hepatic membrane receptor complex, FGFR4 and βKL, triggers 
activation of downstream cellular kinases, such as ERK and GSK, resulting in inhibition of 
hepatic bile acid and glucose synthesis and in stimulation of glycogen and protein synthesis (3, 4, 
7). Interestingly, the hepatic response to FGF19 signaling is impaired in patients with NAFLD, 
despite relatively normal FGF19 production in these patients (9). My current study suggests that 
aberrant miR-34a/FGF19 signaling may explain FGF19 resistance in fatty liver patients. 
Moreover, the miR-34a/βKL/FGF19 axis is likely more relevant in pathological conditions 
where miR-34a levels are aberrantly elevated, because there was no significant correlation 
between miR-34a and βKL levels in response to fasting and feeding under physiological 
conditions (Appendix, Fig. A14). Further, I unexpectedly found that expression of FGFR4, the 
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hepatic membrane receptor for FGF19, is also decreased in obese mice and in mice 
overexpressing the miR-34a. However, FGFR4 is not likely a direct target of miR-34a because 
there is no miR-34a site in the FGFR4 transcript. The present data are consistent with the idea 
that the protein levels and localization of FGFR4 are affected by the levels of its co-receptor 
βKL, but additional experiments will be needed to establish this. 
In vivo antisense inhibition of elevated miR-34a resulted in beneficial metabolic 
outcomes, such as, decreased liver fat and increased liver glycogen, which is consistent with 
expression of glucose and fatty acid metabolic genes (Fig. 10). Although this study focuses on 
the βKL/FGF19 pathway, βKL also functions as a co-receptor for FGF21 in adipose tissue 
during prolonged fasting (5, 6, 23). FGF21 is induced by PPARα in liver in response to 
prolonged fasting (22, 24). Secreted FGF21 activates lipolysis in adipose tissue and β-oxidation 
and ketogenesis in the liver to meet energy demands during starvation.  Therefore, our finding 
that βKL is an in vivo target of miR-34a suggests that aberrantly elevated miR-34a in obesity 
might also result in abnormal βKL/FGF21 signaling and contribute to unfavorable energy 
homeostasis.  Further, it has been shown that miR-34a directly inhibits other genes involved in 
metabolic regulation, including SIRT1 in liver (14) and VAMP2 in pancreatic β-cells (25). 
SIRT1 is a NAD
+
-dependent deacetylase that mediates homeostatic responses to nutrient 
limitation by deacetylating and modulating the activity of metabolic regulators resulting in 
increased β-oxidation and decreased lipogenesis (26-29). VAMP2 plays a key role in insulin 
secretion by regulating exocytosis (25). Therefore, it is possible that the βKL/FGF21 axis, 
SIRT1, and VAMP2 regulatory pathways in the liver and other metabolic tissues, in addition to 
the βKL/FGF19 axis in the liver, contribute to the beneficial metabolic outcomes observed from 
the global in vivo anti-miR-34a experiments. 
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 In addition to the role of FGF19 in fed-state metabolic regulation, abnormal activation of 
FGF19 signaling has been associated with colon and liver cancer (30). Interestingly, miR-34a is 
a well-known tumor suppressor and absence of miR-34a expression due to deletion of its gene 
was associated with liver and colon cancer (31, 32). Consistent with these reports, adenoviral-
mediated overexpression of miR-34a dramatically inhibited tumorigenesis in the liver (33).  
Therefore, our studies suggest a possible molecular mechanism by which miR-34a suppresses 
the development of liver cancer through targeting βKL/FGF19 signaling. Targeting the 
βKL/FGF19 signaling may, therefore, be of value in the treatment of cancer as well as metabolic 
disease, although the signaling would need to be carefully modulated since excess miR-34a is 
associated with metabolic disease and miR-34a deficiency is associated with liver cancer. 
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Chapter Three 
Promoting brown and beige fat production in obesity  
by targeting the miR-34a/FGF21 axis 
1.  Abstract 
 Brown fat generates heat through uncoupled respiration, protecting against hypothermia 
and obesity. Emerging evidence indicates that adult humans have brown fat but the amounts and 
activities are substantially decreased in obesity by unknown mechanisms. Here we show that 
elevated adipocyte miR-34a in obesity inhibits brown fat formation by suppressing the browning 
activators, FGF21 and SIRT1. Downregulation of miR-34a in diet-induced obese mice by 
injection with lentivirus expressing anti-miR-34a substantially reduced adiposity with improved 
serum lipid profiles and increased mitochondria numbers and oxidative function. Remarkably, 
downregulation of miR-34a dramatically increased beige depots in all types of white adipose 
tissue (WAT), including epididymal visceral fat, and promoted additional browning in brown 
adipose tissue. Indeed, expression of anti-miR-34a increased coexpression of beige fat-specific 
CD137 and the general fat browning marker UCP1 in WAT. Mechanistically, downregulation of 
miR-34a restored adipocyte expression of both FGF21 signaling by increasing expression of the 
FGF21 receptor components, FGFR1 and βKL, and also that of SIRT1, resulting in increased 
PGC-1α transcriptional activity via FGF21/SIRT1-dependent deacetylation and induction of 
browning-related genes, Ucp1, Pgc-1α, and Prdm16. This study identifies miR-34a as a novel 
inhibitor of brown and beige fat production in obesity, providing a potential target for treating 
obesity-related diseases.  
 
 
This chapter is under revision in the Molecular and Cellular Biology, will appear most of this 
part in later publication as Fu, T. et al. Promoting brown and beige fat production in obesity by 
targeting the miR-34a/FGF21 axis. 
54 
 
2. Introduction 
 One most basic but important idea in metabolic disease is the concept of energy balance 
and the consequence of imbalance between food intake and energy expenditure. When food 
intake chronically exceeds energy expenditure, weight gain occurs which can result in obesity. 
This excess weight is stored in adipose tissue as lipid droplets in adipocytes. But this tissue is not 
just a passive storage depot, but is also an endocrine organ that secretes molecules like leptin and 
adiponectin, which regulate whole-body metabolism. In addition, there are adipocytes present in 
brown fat that are highly effective at transforming chemical energy into heat. The global 
epidemic of obesity has greatly increased research interest in energy-dissipating brown fat  (1). 
There are two main kinds of adipose tissue: While white adipose tissue (WAT) stores excess 
chemical energy leading to weight gain, brown adipose tissue (BAT) expends energy as heat 
through uncoupled respiration via the action of mitochondria uncoupled protein-1 (UCP1), 
protecting against hypothermia and obesity (2-5). BAT and WAT not only have distinct cellular 
morphology, but also have distinguishable anatomical locations. BAT is mainly located in 
interscapular depots and axial depots, while WAT mainly includes subcutaneous fat, epididymal 
fat, perirenal fat and epicardial fat.  
 BAT was first found in hibernating animals to function in maintaining body temperature, 
but later was also found in small mammals and infants as an adaption to defend against cold. 
BAT increases energy expenditure through the uncoupling of oxidative metabolism from ATP 
production, which is the key function of UCP1 (uncoupling protein 1). This long chain fatty 
acid-activated protein is in the inner membrane of mitochondria and catalyzes a proton leak 
across the inner membrane, dissipating the electrochemical gradient that has been generated via 
the electron transport chain (ETC) (2). Despite having such a different physiological role from 
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brown adipocytes, white adipocytes still share many core molecular components with brown 
adipocytes, such as transcriptional factor PPARγ (3). Interestingly, recent human studies using 2-
flurodeoxyglucose coupled with PET scanning have shown that adult humans have brown fat, 
and the activity and amounts of the brown fat are inversely related with the BMI and are 
substantially decreased in obesity (3, 7).   
 Recent studies have discovered a second type of brown-like fat, “beige fat”, which is 
present as clusters of UCP1-expressing adipocytes with thermogenic capacity within WAT and 
develops in WAT in response to various stimuli and is genetically distinct from classical BAT 
(6). Like brown adipocytes, beige cells in mouse WAT are defined by their multilocular lipid 
droplet morphology, high mitochondrial content and the expression of a core set of brown fat-
specific genes, for example, Ucp1, Pgc1α and Prdm16 (9, 15). Despite the common ability of 
thermogenesis, brown and beige cells have many distinguishing characteristics and should be 
considered as distinct cell types. Beige cells are not derived from the same embryonic (Myf5 
(encoding myogenic factor 5)-expressing) precursors that give rise to brown adipocytes. In 
addition, the two cell types express distinct and distinguishing gene signatures when activated, 
suggesting metabolism in these cell types is differentially regulated. Increasing energy 
expenditure by promoting production of brown fat in BAT and beige fat in WAT, particularly in 
obese individuals, would be an appealing option for weight reduction and for treating obesity-
related diseases.  
 Brown and beige fat depots develop in response to various activators, including cold 
exposure, hormones, exercise, and transcriptional regulators like PRDM16, PPARα, SIRT1, and 
PGC-1α  (8-11). Here, I just highlight studies related to the work in this thesis. Some secreted 
molecules can activate BAT or induce beiging in WAT, such as FGF21 and irisin.  
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 FGF21 has been shown to beneficially affect metabolism and energy balance by 
promoting fat browning in WAT, as well as in BAT, in response to cold exposure and also by 
enhancing fatty acid β-oxidation in mice (12-16). FGF21 is secreted locally by adipose tissue 
under certain conditions such as cold, and regulates browning, at least partially through 
stimulating increased levels of PGC-1α. However, the therapeutic potential of FGF21 is hindered 
by the fact that obesity may be a FGF21 resistant state. Thus obese patients already have high 
endogenous levels of FGF21 and systematic administration of additional FGF21 promotes bone 
loss, possibly through PPARγ. My proposal in this thesis is using anti-miR-34a to restore the 
impaired FGF21 signaling and to promote browning.  
 Another well studied molecule is irisin or FNDC5 (fibronectin type 3 domain-containing 
5). Recently scientists found that PGC-1α is induced during exercise and regulates many 
exercise-related pathways in skeletal muscle (11). FNDC5 is a secreted protein that was 
expressed at higher levels in skeletal muscle post-exercise or with ectopic expression of PGC-1α. 
In vitro treatment of primary adipocytes with FNDC5 protein or adenoviral delivery of FNDC5 
into liver induces thermogenic gene expression, including UCP1 and Cidea, in adipose tissue. A 
cleaved form of FNDC5, named irisin, can be detected in human and mice serum and induces 
browning in WAT. 
 Importantly, a recent human study showed that cold exposure increased circulating levels 
of the brown fat activators, FGF21 and irisin, and treatment with either of these endocrine 
regulators upregulated browning genes and promoted thermogenesis (17). Since PGC-1α is a key 
to the function of both molecules, PGC-1α is likely a key nodal point in the thermogenic 
pathway. The requirement for PGC-1α in brown and beige fat development and function has 
been studied in mice by specifically deleting PGC-1α expression in fat (19). The expression of 
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thermogenic genes at ambient temperature is reduced in both subcutaneous and visceral white fat 
in the absence of PGC-1α, whereas brown fat function largely remains intact, possibly due to 
compensation from other brown-selective regulators, like Prdm16, C/EBPβ (20).  
 Besides PGC-1α, PRDM16 plays a pivotal role in regulating browning. The thermogenic 
genes are greatly induced in the beige fat in transgenic mice expressing PRDM16 compared to 
controls (8). Ectopic expression of both PRDM16 and C/EBPβ showed thermogenic gene 
activation (20, 21). It has been shown that PRDM16 expression can be regulated by miRNAs 
(24).  
 Emerging evidence indicates that microRNAs (miRs) also function as important 
regulators that inhibit brown remodeling of adipocytes. Muscle-enriched miR-133a directly 
downregulated expression of the key transcriptional activator of brown fat differentiation, 
PRDM16, and cold exposure decreased miR-133a levels and promoted brown fat cell 
differentiation (18, 19). Brown adipocyte enriched miR-155 was also shown to inhibit brown fat 
cell differentiation by directly targeting the browning transcription factor C/EBPβ (20). Recent 
miR expression profiling analysis has revealed that miR-34a levels are elevated in adipocytes 
from obese individuals (21), but the functional role of the elevated adipocyte miR-34 in obesity 
remains unknown. 
 In this study, I show that aberrantly elevated adipocyte miR-34a in obesity acts as a novel 
inhibitor of brown fat cell differentiation. Downregulation of miR-34a in dietary obese mice 
dramatically increased beige depots in all types of WATs and promoted additional browning in 
BAT. In mechanistic studies, I show that downregulation of miR-34a increased expression of the 
adipocyte FGF21 receptor complex, FGFR1/βKL, and that of SIRT1, which results in the 
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activation of browning transcriptional program via FGF21/SIRT1-dependent deacetylation of 
PGC1-1α.  
 
3. Materials and Methods 
3.1 Reagents and Materials  
 Antisense-miR-34a, anti-scrambled RNA, the Taqman miRNA assay kit, and siRNA for 
βKL (s96291, s96292), FGFR1 (s66023, s66025), and SIRT1 (s96764, s174220) were purchased 
from Applied Biosystems. Antibodies to βKL (AF2619) were purchased from R&D systems. 
Antibodies to FGFR1 (sc-121), SIRT1 (sc-15404), PGC-1α (sc-13067), RNA polymerase II (sc-
9001), tubulin (sc-8085), and actin (sc-1616) were purchased from Santa Cruz Biotech and 
antibodies for p-ERK (#9101), t-ERK (#4695), and pan acetyl-Lys (#9441) were purchased from 
Cell Signaling Technology. Antibodies for CD137 (ab64836) and UCP1 (ab10983, MAB6158) 
were purchased from Abcam and R&D Systems. Antibodies for βKL (LS-B3568) and FGFR1 
(nb600-1287) used in IHC studies were purchased from LS Biology and Novus Biological, 
respectively. Recombinant FGF21 was expressed in E. coli and purified as previously described  
(14).  
 
3.2 In vitro differentiation, miRNA and siRNA transfection and virus infection in 3T3L1 
cells  
 Mouse 3T3-L1 cells were cultured in DMEM, with 10% FBS, 4.5 mg/ml glucose, 4 mM 
glutamine and 1 mM sodium pyruvate. Two days after cells reached confluence, adipocyte 
differentiation was induced by supplementing the media with 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX, Sigma); 1 µM dexamethasone (DEX, Sigma) and 1.5 µg/ml insulin 
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(sigma). Two days later, media was replaced with media containing only 1.5 µg/ml insulin. This 
media was replenished at 2-day intervals. Seven to ten days post-induction, cells were either 
stained for lipid droplets with Oil Red O (Sigma) or total RNA was extracted and mRNA levels 
of adipogenesis genes, like PPARγ, were checked. Anti-miRNAs and siRNAs were transfected 
into differentiated 3T3-L1 with Neon electroporation (Invitrogen) following the manufacturer’s 
protocol. Adenovirus and lentivirus infection of differentiated 3T3-L1 was done with 10 ng/µl 
polybrene (Santa Cruz).  
 
3.3 Lentivirus preparation 
 Lentivirus encoding an anti-sense RNA to miR-34a (anti-miR-34) and scrambled RNA 
controls (anti-SC) were purchased from System Biosciences Inc (SBI). Lentivirus packaging 
plasmids, pMD2.G and psPAX2 (Addgene), were used to make Lenti-E containing the anti-
scramble miRs and Lenti-miR-34ai containing the anti-miR-34a. The lentivirus was concentrated 
with PEG-it virus precipitation solution (#LV825A, SBI). Lentivirus was titrated using SBI 
Global UltraRapid Lentiviral Titer kit (#LV961A, SBI). 
 
3.4 Animal experiments 
 To produce diet-induced obese mice, six to eight week-old male BALB/c mice or 
C57BL/6 mice (The Jackson Laboratory) were fed a HFD (60% fat, Research Diets, Inc.) for 16 
to 24 weeks. Lentiviral vectors encoding an anti-sense miR-34a (anti-miR-34) or scrambled 
controls (anti-sc) were purchased from System Biosciences Inc. Lentivirus packaging plasmids, 
pMD2.G and psPAX2 (Addgene), were used to make Lenti-E containing anti-scrambled miRs 
and Lenti-miR-34ai. BALB/c mice (10 mice/group) were injected with lentivirus via tail veins at 
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doses of 2 x 109 pfu in 100 µl PBS and sacrificed 14-21 days after the injection, and adipose 
tissue, liver, and serum samples were collected. For in vivo FGF21 signaling studies, mice (3 
mice/group) were injected i.p. with FGF21 (0.5 mg/kg or 1 mg/kg) and 30 min later, adipose 
tissues from 3 mice were pooled for preparing adipose extracts. We observed that the C57BL/6 
mice were more prone to diet-induced obesity but after injection of lentivirus expressing anti-
miR-34a, increased expression of browning-related genes, such as Ucp1, Pgc-1α, and Prdm16, in 
eWAT from the C57BL/6 (Appendix, Fig. B8) was comparable to that from the BALB/c mice 
(Appendix, Fig. B2).  All animal use protocols were approved by the Institutional Animal Care 
and Use and Institutional Biosafety Committees at University of Illinois at Urbana-Champaign.  
 
3.5 IHC studies  
 Primary antibodies to UCP1 and CD137 were visualized using a biotin-labeled secondary 
antibody and peroxidase-coupled streptavidin kit (Abcam), and the samples were imaged with a 
NanoZoomer Scanner (Hamamatsu).  For the fluorescent IHC, secondary antibodies labeled with 
either Alexa 647 or Alexa 488 were used.  The nucleus was stained with DAPI (Invitrogen). The 
samples were imaged by confocal microscopy (Zeiss LSM 700).  
 
3.6 Mitochondrial DNA copy number 
 Total DNA was isolated using a DNA extraction kit (Omega Bio-Tek). A serial dilution 
standard curve was prepared and DNA was quantified by qPCR. The mitochondrial DNA copy 
number was calculated from the ratio of the DNA of COX II, a mitochondria gene, to that of 
cyclophilin A, a single copy nuclear gene.  
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3.7 Citrate synthase (CS) activity assay  
 CS activity was measured with a kit (Sigma-Aldrich) according to the manufacturer’s 
instructions.  A total of 2 µg of protein from scWAT, gWAT, or BAT were used for the assay. 
 
3.8 Construction of Fgfr1 3’UTR-luc plasmids and luciferase assay   
 A SpeI/ HindIII fragment containing the 3’UTR of FGFR1 was amplified by PCR and 
inserted into the pMIR plasmid. Mutations were made using a site-directed mutagenesis kit 
(Stratagene) and confirmed by DNA sequencing. Luciferase assays were performed as 
previously described (36-38). 
 
3.9 q-RTPCR 
 MicroRNAs were isolated using the mirVana™ miRNA Isolation Kit (Ambion).  Levels 
of miR-34a were determined by q-RTPCR and normalized to snoRNA202 (Ambion).  For 
mRNA levels, total RNA was isolated with Trizol and levels were determined by q-RTPCR 
normalized to 36B4. Primer sequences are available in the Supplemental Information (Appendix, 
Table B1). 
 
3.10 PGC-1α acetylation and ChIP assay   
 WAT tissues were pooled from 3 mice and extracts were prepared and immediately used 
for IP/IB acetylation assays as previously described (36-38). The IP buffer contained 1 µM TSA 
and 10 mM NAM to inhibit deacetylation. Occupancy of PGC-1α and RNA polymerase II at 
browning genes was determined by ChIP assays in differentiated 3T3-L1 cells as previously 
described
 
(36-38). 
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4. Results 
4.1 Downregulation of miR-34a reduces adiposity in diet-induced obese mice  
 To investigate functional roles of elevated miR-34a in obesity, I downregulated miR-34a 
by lentiviral-mediated expression of antisense-miR-34a in obese mice fed a high fat diet (HFD).  
Expression of anti-miR-34a in obese mice reduced adipocyte miR-34a levels in WAT and BAT 
near to those in lean mice (Fig. 11A) and significantly reduced body weight (Fig. 11B), while 
food intake was not changed (Appendix, Fig. B1). Consistent with weight reduction, the amounts 
of abdominal fat (Fig. 11C), and different types of visceral epididymal eWATs, perirenal WAT 
(prWAT) and gonadal WAT (gWAT), as well as subcutaneous WAT (scWAT), were 
substantially reduced as was the amount of BAT (Fig. 11D). The weights of adipose tissue (Fig. 
11E) and adipocyte sizes (Fig. 11F, G), particularly in WAT, were markedly reduced in mice 
expressing anti-miR-34a. Notably, all types of WATs, including visceral gWAT and 
subcutaneous scWAT, had a brownish color in obese mice expressing anti-miR-34a (Fig. 11D). 
Consistent with decreased adiposity, serum levels of triglycerides, FGF21 and fatty acids were 
substantially decreased in anti-miR-34a-expressing mice (Fig. 11H). These results indicate that 
silencing of miR-34a in obese mice reduced adiposity and possibly, promoted fat browning in 
both WAT and BAT.  
 
4.2 Downregulation of miR-34a in obese mice increased brown fat differentiation in both 
WAT and BAT   
 I examined in more detail the effects of anti-miR-34a on fat browning. Remarkably, 
dramatic increases were observed in brown fat-like beige depots, detected by UCP1 expression, 
in visceral eWATs, such as prWAT and gWAT, and in subcutaneous scWAT as well as in BAT 
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(Fig. 12A). Further, in all types of WATs, multilocular fat droplets, characteristic of brown fat 
cells, were evident in obese mice expressing anti-miR-34a (Fig. 12A). Mitochondrial numbers 
were also increased (Fig. 12B) and the activity of citrate synthase, a marker for mitochondrial 
oxidative function, was also highly increased in both WAT and BAT in anti-miR-34a-expressing 
mice (Fig. 12C). Expression of the browning-related genes, Ucp1, Pgc-1α, and Prdm16, was 
increased in each type of WAT, prWAT, gWAT, and scWAT, as well as, in BAT by 
downregulation of miR-34a (Fig. 12D-F). I also examined expression of lipid handling genes in 
adipose tissues from visceral and subcutaneous WATs. The expression of most lipolysis genes 
and lipid uptake genes was increased, whereas that of all tested lipogeneic genes and 
inflammatory genes, Tnfα and IL6, was decreased in eWAT from mice expressing anti-miR-34a 
(Fig. 12F). Notably, while expression of the key browning gene activator PRDM16 was 
increased in WAT (Fig. 12E, Appendix, Fig. B2) and BAT, expression of TLE3, a white fat-
selective cofactor antagonizing PRDM16 action (28), was decreased in eWAT (Fig. 12F) from 
mice expressing anti-miR-34a. These striking findings indicate that in vivo silencing of miR-34a 
in dietary obese mice promoted beige-like browning in all types of WATs, both visceral and 
subcutaneous fat, and increased additional browning in BAT.  
 
4.3 Downregulation of miR-34a in obesity promoted beige fat production in all types of 
WATs 
 Recent evidence indicates that there are two distinct types of brown fat cells, a myf-5 
positive/UCP1 positive classical brown fat cell and a myf-5 negative/UCP1-positive beige fat 
cell that is present in WAT (6,29,45). Importantly, gene expression patterns in beige fat cells are 
distinct from those in either classical BAT or WAT (7). To definitively determine whether the 
64 
 
browning observed in WAT was due to beige fat derived from myf-5 negative precursor cells, I 
examined the coexpression of beige fat-specific CD137 (7) and the general fat browning marker 
UCP1. While CD137 was not detected in BAT as expected (7), expression of both CD137 and 
UCP1 was increased in all types of WATs in mice expressing anti-miR-34a (Fig. 13A-D). These 
results indicate that in vivo silencing of elevated miR-34a in obese mice promoted 
CD137/UCP1-positive beige fat cell differentiation in all types of WATs.  
 
4.4 Adipocyte miR-34a and FGFR1/βKL levels are inversely correlated 
 I next investigated the possible mechanisms for fat browning in dietary obese mice 
expressing anti-miR-34a. Recent studies have shown that FGF21 promotes brown and beige fat 
formation in adaptive thermogenesis (15, 29). Surprisingly, a conserved miR-34a seed sequence 
was detected within the 3’UTR of the FGF21 receptor, FGFR1 (Fig. 14A). Further, I have shown 
that miR-34a attenuated hepatic FGF19 signaling by directly targeting βKL (28). βKL is the 
membrane coreceptor not only for FGF19 but also for FGF21 in liver and adipose tissue (29). I, 
therefore, hypothesized that miR-34a inhibits fat browning in part by targeting both components 
of the FGF21 receptor complex, FGFR1 and βKL. Indeed, in WAT of obese mice, there was a 
strong inverse correlation between adipocyte miR-34a levels and both mRNA (Fig. 14B) and 
protein (Fig. 14C) levels of FGFR1/βKL. An inverse correlation between miR-34a and 
FGFR1/βKL protein levels were also detected in differentiated 3T3-L1 cells (Fig. 14D, E, 
Appendix, Fig. B3), supporting this hypothesis.  
4.5 MiR-34a attenuates FGF21 signaling by directly targeting FGFR1  
 
 To determine whether FGFR1 is a direct target of miR-34a, the miR-34a binding 
sequence in the FGFR1 3’UTR or a mutated sequence was inserted into a luciferase reporter 
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(Appendix, Fig. B4). Downregulation of miR-34a increased reporter activity for the wild type 
(WT) sequences, but not the mutated sequences and conversely, overexpression of miR-34a 
inhibited the reporter activity only for the WT sequence (Fig. 14F, G). These results indicate that 
miR-34a directly downregulates FGFR1 and that the inhibition is likely mediated by binding of 
miR-34a to the 3’ UTR of the FGFR1 mRNA.  
 
4.6 In vivo silencing of miR-34a in dietary obese mice increased expression of the adipocyte 
FGF21 receptor complex and restored FGF21 signaling  
 I next examined the effects of miR-34a on FGF21 signaling by performing gain- and 
loss-of-function experiments in differentiated 3T3 cells. FGF21-mediated phosphorylation of 
ERK is a measure of FGF21-responsiveness (31, 32). FGF21 treatment increased levels of 
activated p-ERK, but these effects were not detected in cells overexpressing miR-34a and 
conversely, downregulation of miR-34a increased p-ERK levels (Fig. 15A, B), indicating that 
miR-34a attenuates adipocyte FGF21 signaling.  
 I further examined whether miR-34a acts similarly in eWAT in mice in vivo (Fig. 15C).  
Expression of anti-miR-34a in dietary obese mice increased mRNA levels of Fgfr1 and βKL and 
of the early FGF21 target genes, Erg-1 and c-Fos (31) (Appendix, Fig. B5), and increased protein 
levels of the FGF21 receptor complex, FGFR1 and βKL (Fig. 15D). In vivo FGF21 treatment 
increased p-ERK levels in lean mice but these responses were blunted in obese mice (Fig. 15E).  
Importantly, lentiviral-mediated expression of anti-miR-34a increased p-ERK and p-AMPK 
levels in WAT in obese mice in response to FGF21 treatment (Fig. 15E, F). These results 
indicate that adipocyte FGF21 signaling is impaired in obesity and that downregulation of miR-
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34a restores FGF21 sensitivity, which is consistent with decreased serum FGF21 levels resulting 
from expression of anti-miR-34a in obese mice (Fig. 11H).  
 
4.7 In vivo silencing of miR-34a increased adipocyte SIRT1 levels and deacetylation of 
PGC-1α 
 A cold-inducible transcriptional coactivator PGC-1α  has crucial roles in mitochondria 
biogenesis (34) and browning of WAT in adaptive thermogenesis and in induction of a beige fat-
promoting mitokine, irisin, during exercise (15, 18). Transcriptional activity of PGC-1α is 
profoundly increased by SIRT1-dependent deacetylation (35). Since hepatic SIRT1 is also a 
direct target of miR-34a 
 
(37, 38), I further asked whether downregulation of miR-34a increases 
SIRT1 expression in WAT. The reduced protein levels of adipocyte SIRT1 in obese mice were 
completely reversed (Fig. 15G) and acetylated PGC- 1α levels (Fig. 15H) were substantially 
decreased by anti-miR-34a expression in both control and FGF21-treated mice. These findings 
suggest that downregulation of SIRT1 and the FGF21 receptor complex by miR-34a increases 
PGC-1α acetylation, which would result in decreased activity of PGC-1α. 
 
4.8 FGF21 signaling and SIRT1 are critical for PGC-1α deacetylation and the browning 
gene program induced by anti-miR-34a  
 To determine the relative importance of FGF21 signaling and SIRT1 for deacetylation of 
PGC-1α and the browning gene program, I performed combined antisense-miR-34a and siRNA 
experiments in differentiated 3T3-L1 fat cells (Fig. 16A). FGF21 treatment increased p-ERK 
levels but these increases were abolished when either FGFR1 or βKL was downregulated by 
siRNA (Fig. 16B, C). Anti-miR-34a decreased levels of acetylated of PGC-1α and the decrease 
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was reversed by SIRT1 siRNA as expected (Fig. 16D). Surprisingly, treatment with siRNA for 
FGFR1 or βKL also resulted in increased acetylation of PGC-1α (Fig. 16D), suggesting that 
deacetylation of PGC-1α is dependent on both FGF21 and SIRT1 functions.   
 Consistent with increased acetylation and decreased gene activity of PGC-1α (35), 
downregulation of FGFR1/βKL or SIRT1 resulted in reduced occupancy of PGC-1α and RNA 
polymerase II at the browning-related genes, Ucp1, Prdm16, Pparγ, and C/ebpβ (Fig. 16E) and 
decreased expression of these browning genes (Fig. 16F), mitochondria numbers (Fig. 16G), and 
UCP1 protein levels (Fig. 16H, Appendix, Fig. B6). These results, together with findings from 
the in vivo studies above, demonstrate that downregulation of the elevated miR-34a in obesity 
promoted brown fat cell differentiation and that both FGF21 signaling and SIRT1 functions are 
important for the induction of browning genes by increasing transcriptional activity of PGC-1α 
via protein deacetylation.  
 
5.  Discussion 
 
 This study identifies elevated adipocyte miR-34a in obesity as a novel inhibitor of brown 
fat cell differentiation. Downregulation of miR-34a in diet-induced obese mice increased 
expression of both components of the adipocyte FGF21 receptor complex, FGFR1 and βKL, and 
also SIRT1 deacetylase, which resulted in increased PGC-1α browning gene activity mediated by 
FGF21/SIRT1-dependent deacetylation of PGC-1α (Fig. 17). These molecular events contributed 
to increased beige fat formation in all types of WATs, even including visceral fat, and promoted 
additional browning in BAT.   
 FGF21 has beneficial impacts on energy homeostasis by promoting mitochondria 
oxidative metabolism and brown and beige fat production  (29,44-45). Notably, circulating 
FGF21 levels are highly elevated in obese individuals with metabolic syndrome (40), suggesting 
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that FGF21 signaling might be impaired in obesity (32) but FGF21 resistance in obesity has been 
controversial in mouse studies  (17, 32, 41) . My data, however, indicate that FGF21 signaling is 
impaired in diet-induced obese mice under my experimental conditions, in agreement with such 
resistance in obesity (34). I further provide a mechanistic basis for the FGF21 resistance by 
showing that elevated miR-34a attenuates FGF21 signaling by directly downregulating 
expression of the adipocyte FGF21 receptor complex, FGFR1 and βKL.  In addition to its role in 
adipocytes, we also observed that downregulation of miR-34a restored hepatic FGF21 signaling 
and increased expression of hepatic genes involved in fatty acid oxidation, Cpt1, Mcad, Eci, 
CytC, and Pparα and decreased lipogenic genes, Fas and Srebp-1c (Appendix, Fig. B7). Anti-
miR-34a-mediated beneficial effects on fatty acid metabolism and fat browning in liver and 
adipose tissue by restoring FGF21 sensitivity in the present study are consistent with 
amelioration of liver steatosis and insulin resistance in obese mice after multiple injections of 
antisense oligonucleotides for miR-34a (27, 32) .  
PGC-1α was recently shown to be important for FGF21-mediated fat browning upon cold 
exposure and FGF21 was shown to increase PGC-1α protein levels without affecting protein 
stability (15), but how the transcriptional activity of PGC-1α is upregulated during brown 
adipocyte differentiation is still unclear. My studies suggest that a post-translational 
modification, deacetylation, of PGC-1α is important for linking FGF21 signaling and induction 
of PGC-1α target browning genes. PGC-1α acetylation levels were increased by downregulation 
of SIRT1, as expected (32, 36) , but surprisingly also by downregulation of FGFR1/βKL, 
suggesting that both FGF21 signaling and SIRT1 function are important for deacetylation of 
PGC-1α and its browning gene activity.  The precise mechanism by which FGF21 signaling 
promotes SIRT1-dependent deacetylation of PGC-1α requires further investigation, but increased 
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AMPK activity may play a role. FGF21 was shown to enhance mitochondrial oxidation by 
activating the AMPK/SIRT1/PGC-1α cascade pathway (43) and AMPK increases energy 
expenditure by upregulating SIRT1 activity (42). Indeed, I observed that FGF21 signaling 
increased p-AMPK levels in adipocytes (Fig. 15F). Future studies will be required to understand 
how FGF21 and SIRT1 signaling pathways are integrated to regulate the acetylation status of 
PGC-1α and the browning gene program. Notably, each of these components, FGFR1, βKL, and 
SIRT1, is a direct target of miR-34a, suggesting that miR-34a, aberrantly elevated in obesity, is a 
key upstream regulator of the major factors in the cellular network that controls energy 
metabolism and fat browning.  
 Although the present study focused on the effect of downregulation of elevated miR-34a 
in obesity on fat browning, I also observed that cold exposure of 3T3-L1 fat cells resulted in 
decreased miR-34a levels and dramatic increases in mitochondria numbers and expression of the 
browning genes, Ucp1, Pgc-1α, and Prdm16, and browning differentiation and that 
overexpression of miR-34 completely reversed these cold temperature-induced browning effects 
(Appendix, Fig. B9). Consistent with these results, a recent miR expression profiling showed that 
miR-34a was among the miRs that were downregulated upon cold temperature (23). My findings 
from cold exposure studies in 3T3 fat cells, together with in vivo anti-miR-34a studies in diet-
induced obese mice, suggest that miR-34a may function as a general inhibitor of brown fat 
differentiation in adaptive thermogenesis, as well as, under pathological obese conditions.  
 Increasing energy expenditure by promoting the heat-generating brown fat production in 
BAT would be an appealing option for treating obesity-related metabolic disorders. However, 
there are limited amounts of BAT in adult humans and more importantly, BAT is substantially 
reduced and WAT is increased in obese individuals (8, 45, 46), so it is not clear whether 
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targeting BAT would have a significant impact on overall energy balance and weight reduction 
in obese patients. Moreover, it is well known that abdominal visceral adiposity strongly 
correlates with metabolic syndrome and insulin resistance (45). In this regard, one of the exciting 
and therapeutically relevant findings from the present study is that in vivo silencing of miR-34a 
in diet-induced obese mice, not only increased brown fat depots in BAT, but also dramatically 
increased beige depots in all types of WATs, even in the abdominal visceral fat. To my 
knowledge, this is the first report showing that the formation of beige fat is promoted in obese 
animals by downregulation of an elevated microRNA. The striking effects of anti-miR-34a on 
promoting fat browning in all types of adipose tissues, together with its beneficial effects on 
amelioration of liver steatosis and insulin resistance (16, 36), suggest that targeting a single 
microRNA in obesity, miR-34a, which inhibits expression of multiple key players of oxidative 
metabolism and fat browning, may provide an effective therapeutic option for combating obesity 
and related metabolic disorders.  
 
6.  Acknowledgments 
 I thank Dr. Kai Ge at the NIH for technical guidance for 3T3-L1 fat cell experiments. I 
also thank Dr. Mayandi Shivaguru and Ms. Donna Epps in core facility center of Institute of 
Genomic Biology and Ms. Karen Doty in College of Veterinary Medicine Histology Laboratory 
at the UIUC for their help in the histology studies. I also thank Dr. Lucas Li in the metabolomics 
center at the UIUC for measurement of metabolites. This study was supported by grants from the 
National Institutes of Health (DK62777 and DK95842) and American Diabetes Association 
(Basic Science Award) to JKK.  
 
71 
 
7.  Author Contributions 
 Ting Fu, Sunmi Seok, Sunge Choi, Zhang Huang, Kelly Suino-Powell, H. Eric Xu, Byron 
Kemper, and Jongsook Kim Kemper. (TF and JK designed research; TF, SS, SC, and ZH 
performed experiments; KSP and HEX provided purified FGF21 for in vivo experiments; TF, 
BK, and JK analyzed data; and TF, BK, and JK wrote the paper.) 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
8. Figures and Tables 
 
73 
 
 
 
74 
 
 
 
75 
 
 
 
76 
 
 
 
77 
 
 
 
78 
 
 
79 
 
9. References 
1. Rosen, E. D. & Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose 
homeostasis. Nature 444, 847-853 (2006). 
2. Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. 
Physiol. Rev. 84, 277-359 (2004). 
3.Gesta, S., Y.H. Tseng, and C.R. Kahn, Developmental origin of fat: tracking obesity to its 
source. Cell, 2007. 131(2): p. 242-56. 
4. Cypess, A. M. et al. Identification and importance of brown adipose tissue in adult humans. N. 
Engl. J. Med. 360, 1509-1517 (2009). 
5. Kajimura, S., Seale, P. & Spiegelman, B. M. Transcriptional control of brown fat 
development. Cell. Metab. 11, 257-262 (2010). 
6. Harms, M. & Seale, P. Brown and beige fat: development, function and therapeutic potential. 
Nat. Med. 19, 1252-1263 (2013). 
7. Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. 
Cell 150, 366-376 (2012). 
8. Vijgen, G. H. et al. Brown adipose tissue in morbidly obese subjects. PLoS One 6, e17247 
(2011). 
9. Seale, P. et al. Prdm16 determines the thermogenic program of subcutaneous white adipose 
tissue in mice. J. Clin. Invest. 121, 96-105 (2011). 
10. Ohno, H., Shinoda, K., Spiegelman, B. M. & Kajimura, S. PPARgamma agonists induce a 
white-to-brown fat conversion through stabilization of PRDM16 protein. Cell. Metab. 15, 395-
404 (2012). 
11. Bostrom, P. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development 
of white fat and thermogenesis. Nature 481, 463-468 (2012). 
12. Qiang, L. et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation 
of Ppargamma. Cell 150, 620-632 (2012). 
13. Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated 
induction of fibroblast growth factor 21. Cell Metab 5, 415-425 (2007). 
14. Badman, M. K. et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a 
key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5, 426-437 (2007). 
  
80 
 
15. Fisher, F. M. et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in 
adaptive thermogenesis. Genes Dev. 26, 271-281 (2012). 
16. Dutchak, P. A. et al. Fibroblast growth factor-21 regulates PPARgamma activity and the 
antidiabetic actions of thiazolidinediones. Cell 148, 556-567 (2012). 
17. Canto, C. & Auwerx, J. Cell biology. FGF21 takes a fat bite. Science 336, 675-676 (2012). 
18. Lee, P. et al. Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat 
Function in Humans. Cell. Metab. 19, 302-309 (2014). 
19.Kleiner, S., et al., Development of insulin resistance in mice lacking PGC-1alpha in adipose 
tissues. Proc Natl Acad Sci U S A, 2012. 109(24): p. 9635-40. 
 
20.Kajimura, S., P. Seale, and B.M. Spiegelman, Transcriptional control of brown fat 
development. Cell Metab, 2010. 11(4): p. 257-62. 
 
21.Jimenez-Preitner, M., et al., Plac8 is an inducer of C/EBPbeta required for brown fat 
differentiation, thermoregulation, and control of body weight. Cell Metab, 2011. 14(5): p. 658-70. 
 
22.Seale, P., et al., Transcriptional control of brown fat determination by PRDM16. Cell Metab, 
2007. 6(1): p. 38-54. 
23. Trajkovski, M. & Lodish, H. MicroRNA networks regulate development of brown 
adipocytes. Trends Endocrinol. Metab. 24, 442-450 (2013). 
24. Trajkovski, M., Ahmed, K., Esau, C. C. & Stoffel, M. MyomiR-133 regulates brown fat 
differentiation through Prdm16. Nat. Cell Biol. 14, 1330-1335 (2012). 
25. Yin, H. et al. MicroRNA-133 controls brown adipose determination in skeletal muscle 
satellite cells by targeting Prdm16. Cell. Metab. 17, 210-224 (2013). 
26. Chen, Y. et al. miR-155 regulates differentiation of brown and beige adipocytes via a 
bistable circuit. Nat. Commun. 4, 1769 (2013). 
27. Ortega, F. J. et al. MiRNA expression profile of human subcutaneous adipose and during 
adipocyte differentiation. PLoS One 5, e9022 (2010). 
28. Villanueva, C. J. et al. Adipose subtype-selective recruitment of TLE3 or Prdm16 by 
PPARgamma specifies lipid storage versus thermogenic gene programs. Cell. Metab. 17, 423-
435 (2013). 
29. Wu, J., Cohen, P. & Spiegelman, B. M. Adaptive thermogenesis in adipocytes: is beige the 
new brown? Genes Dev. 27, 234-250 (2013). 
81 
 
30. Kajimura, S. et al. Regulation of the brown and white fat gene programs through a 
PRDM16/CtBP transcriptional complex. Genes Dev. 22, 1397-1409 (2008). 
31. Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) 
receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 
26687-26695 (2007). 
32. Fisher, F. M. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 
59, 2781-2789 (2010). 
33. Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive 
thermogenesis. Cell 92, 829-839 (1998). 
34. Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the 
thermogenic coactivator PGC-1. Cell 98, 115-124 (1999). 
35. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-
1alpha and SIRT1. Nature 434, 113-118 (2005). 
36. Fu, T. et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to 
FGF19 by targeting a membrane coreceptor beta-Klotho. Proc. Natl. Acad. Sci. U. S. A. 109, 
16137-16142 (2012). 
37. Choi, S. E. et al. Elevated microRNA-34a in obesity reduces NAD levels and SIRT1 activity 
by directly targeting NAMPT. Aging Cell. 12, 1062-1072 (2013). 
38. Lee, J. et al. A pathway involving farnesoid X receptor and small heterodimer partner 
positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J. Biol. Chem. 285, 
12604-12611 (2010). 
39. Chau, M. D., Gao, J., Yang, Q., Wu, Z. & Gromada, J. Fibroblast growth factor 21 regulates 
energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc. Natl. Acad. Sci. 
U. S. A. 107, 12553-12558 (2010). 
40. Mraz, M. et al. Serum concentrations and tissue expression of a novel endocrine regulator 
fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf) 
71, 369-375 (2009). 
41. Hale, C. et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin 
resistance. Endocrinology 153, 69-80 (2012). 
42. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against 
metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122 (2006). 
43. Canto, C. et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and 
SIRT1 activity. Nature 458, 1056-1060 (2009). 
82 
 
44. Frontini, A. & Cinti, S. Distribution and development of brown adipocytes in the murine and 
human adipose organ. Cell. Metab. 11, 253-256 (2010). 
45. Lidell, M. E. et al. Evidence for two types of brown adipose tissue in humans. Nat. Med. 19, 
631-634 (2013). 
46. Despres, J. P. et al. Abdominal obesity and the metabolic syndrome: contribution to global 
cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28, 1039-1049 (2008). 
47. Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 
but constitutively elevated in metabolic disease states. Cell Metabolism 10, 392-404 (2009).  
83 
 
Chapter Four 
Transcriptional regulation of autophagy by an FXR/CREB axis  
1. Abstract 
 Lysosomal degradation of cytoplasmic components by autophagy is essential for cellular 
survival and homeostasis under nutrient-deprived conditions (1-4). Short-term regulation of 
autophagy by nutrient-sensing kinases is well defined  (3, 5-7), but longer-term transcriptional 
regulation is relatively unknown. Here we show that the fed-state sensing nuclear receptor FXR  
(8, 9) and the fasting transcriptional activator CREB (10, 11) coordinately regulate the hepatic 
autophagy gene network. Pharmacological activation of FXR repressed many autophagy genes 
and inhibited autophagy, and feeding-mediated inhibition of macroautophagy was largely 
attenuated in FXR-knockout mice. In analyses of mouse liver ChIP-seq data  (12-15), FXR and 
CREB binding peaks were detected at 178 and 112, respectively, of 230 autophagy-related genes, 
and 78 genes showed shared binding, mostly in their promoter regions. CREB activated 
autophagic degradation of lipids, known as lipophagy, under nutrient-deprived conditions and 
FXR inhibited this response. Mechanistically, CREB upregulated autophagy genes, including 
Atg7, Ulk1, and Tfeb, by recruiting its coactivator CRTC2 under fasting. After feeding or 
pharmacological activation, FXR trans-repressed these genes by disrupting the functional 
CREB/CRTC2 complex. This study identifies the novel FXR/CREB axis as a key physiological 
switch regulating autophagy, resulting in sustained nutrient regulation of autophagy during 
feeding/fasting cycles.  
This chapter is under revision in the Nature, will appear most of this part in later publication as 
Seok, S and Fu, T. et al. Transcriptional regulation of autophagy by FXR/CREB axis. 
# 
SS and 
TF equally contributed to this study. 
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2. Introduction 
Autophagy is responsible for the turnover of long-lived intracellular structural proteins 
which are damaged or functionally redundant. The process is essential for maintenance of 
cellular homeostasis and is usually activated in starvation or under stress conditions. Autophagy 
is dynamically regulated in response to nutritional status during feeding and fasting cycles (3, 4, 
16). Dysregulation of autophagy contributes to aging and related diseases like neurodegeneration, 
cardiomyopathy and cancer (2). Recent studies also show that hepatic autophagy is defective in 
obesity and diabetes and its up-regulation improves insulin sensitivity (2, 3). Recent evidence 
demonstrates that, not only is hepatic autophagy severely depressed in dietary-induced (HFD) 
and genetic (ob/ob, db/db) mice models of obesity and diabetes by the severe downregulation 
(>90%) of autophagy network (ATG) proteins, like LC3, ATG7 and ATG5, but the depressed 
autophagy may contribute to impaired insulin sensitivity in these models. The suppression of 
hepatic ATG7 using shRNAi in lean control mice resulted in insulin resistance and ER stress 
(39). Similarly, suppression of ATG7 or ATG5 in cells in vitro caused defective insulin signaling. 
Conversely, restoration of hepatic autophagy in HFD or ob/ob mice by means of overexpression 
of ATG7, diminished ER stress, counteracted insulin resistance, improved hepatic fat 
metabolism and decreased gluconeogenesis (39). Although the underlying mechanism still not 
known, these results suggest that upregulating autophagy may combat insulin resistance and treat 
obesity. 
The autophagy components were initially extensively studied in yeast then later in 
mammalian cells. The key steps are similar but the regulation of autophagy appears to be more 
highly complicated in mammals. This complicated process includes induction of autophagy, 
autophagosome formation, autophagosome fusion with lysosomes, and lysosome degradation 
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and reuse. In a simple word, a portion of cytoplasm or organelles is enclosed by phagophore or 
isolation membrane to form an autophagosome, the outer membrane of the autophagosome 
subsequently fused with an endosome and then the lysosome, and the internal material is 
degraded.    
Although the reason why autophagy can increase insulin sensitivity has not been 
elucidated yet, studies show that autophagy mediates lipid and glycogen digestion.  Therefore in 
this thesis, we mainly studied hepatic autophagy function, here we focus on lipophagy and 
glycophagy in liver. The liver serves as the second largest repository of stored lipids in the body 
after adipose tissue. Hepatocytes are a major cellular storeroom for neutral lipids in the form of 
TGs (triglycerides) and cholesterols, which are contained in specialized organelles called lipid 
droplets. Lipid droplets in adipose tissue are mainly digested by cytosolic lipases. However, 
compared to adipocytes, hepatocytes have a relative paucity of cytosolic lipases. For this reason, 
it had been previously unclear as to how hepatocyte could rapidly mobilize their lipid stores in 
times of metabolic need. Lipids can be degraded in lysosomes which contain acidic lipases and 
breakdown exogenous lipoproteins as well. The loss of hepatocyte autophagy (Atg7 knock-out 
mice) leads to a marked increase in hepatic TG and cholesterol content, demonstrating that 
lipophagy limits hepatocyte lipid accumulation in vivo (36, 39). Moreover, biochemical, 
fluorescence and electron microscopy studies found an increased association of autophagosomal 
protein LC3 with lipid droplets in mouse livers during starvation (36). In addition to serving as a 
mechanism to regulate intracellular lipid stores, lipophagy controls cellular energy hemostasis by 
providing FFAs (free fatty acids) from the breakdown of TGs. FFAs drive mitochondrial β-
oxidation of FFA and cellular ATP production. Thus, lipophagy not only regulates amounts of 
passively stored lipid, but also actively maintains cellar metabolism and energy balance. 
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Similarly, glycophagy refers to autophagy that breaks down glycogen as an energy 
resource. Glycophagy was studied as a function of autophagy at very early stage of the 
autophagy discovery, but due to technical difficulties, few studies have been done so far. In this 
thesis, I propose a new way to fluorescently label glycogen in hepatocytes in order to observe the 
effect of autophagy on glycogen content. Currently, most studies of glycophagy in mammals are 
done in new-born mice which primarily use glycogen as an energy source or in glycogen storage 
disease patients who have excessive amounts of stored glycogen. Since glycogen is used as an 
earlier energy source compared to lipid during nutrient deprivation, a careful studies of the 
effects of autophagy as a function of time or a good animal model is needed to explore the 
physiological role of autophagy in glycogen metabolism. 
Autophagy is commonly considered as a cytoplasmic event, thus, most regulation studies 
have concerned the cytoplasmic kinase regulatory pathways. Post-translational regulation of 
autophagy components by nutrient-sensing kinases, including mTOR and AMPK, has been 
intensively studied (3, 5-7). The kinase mTOR is an important regulator of autophagy induction. 
mTOR can control the nuclear localization of nutrient-regulated transcriptional factors. Upon 
activation, mTOR prevents the transcription of genes by phosphorylating the GATA 
transcription factor, Gln3, causing its retention in the cytoplasm. Gln3 induces ATG gene 
expression, thus, its retention in the cytoplasm suppresses autophagy. Conversely, inhibition of 
mTOR activity causes the dephosphorylation and nuclear translocation of Gln3 and, thus, 
promotion of autophagy. 
While short-term regulation by kinases is well studied, the sustained longer-term 
transcriptional regulation of autophagy is well defined yet and is just beginning to be understood.  
Recent studies have identified a series of tightly controlled transcriptional factors, such as TFEB 
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and ZKSCAN3 that regulate autophagy. In this thesis, we discovered a hepatic FXR/CREB axis 
also functions as a master switch to regulate hepatic autophagy. Below I discuss the 
TFEB/ZKSCAN3 axis since it relevant to our study.  
TFEB was shown to function as a key activator of autophagy/lysosomal gene networks 
during starvation (17, 18). TFEB is a member of the basic helix-loop-helix Leu zipper family, a 
master regulator of lysosomal biogenesis and function. It promotes the transcription of several 
lysosomal genes by directly binding to their promoters. Under normal conditions, TFEB resides 
in the cytoplasm, however, upon starvation, it rapidly translocates to the nucleus, and function as 
a transcriptional factor. ZKSCAN3 (zinc-finger protein with KRAB and SCAN domains 3), a 
DNA-binding protein, seems to be the counterpart of TFEB. It acts as a transcriptional repressor 
of a series of autophagy-related genes. Knockdown of ZKSCAN3 induces autophagy and 
increases lysosome biogenesis. Furthermore, while TFEB is positively regulated by starvation, 
ZKSCAN3 is negatively regulated, which suggests that they act in conjunction with each other. 
Other transcriptional factors and histone modifying proteins were also shown to control 
autophagy (19-22), but their physiological relevance and the underlying mechanisms are not 
clear. Metabolic nuclear receptors function as intracellular biosensors for lipid metabolites and 
nutrients, including bile acids and fatty acids (8, 23), and transduce the nutrient signals into 
transcriptional programming to maintain homeostasis. The nuclear receptor FXR is activated by 
elevated bile acid levels after feeding and controls postprandial responses (24-26). Since FXR is 
a fed-state sensing gene regulator, we postulated that FXR transcriptionally represses hepatic 
autophagy in the nutrient-rich postprandial period.  
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3. Materials and Methods 
3.1 Method Summary 
 Male C57BL/6 WT mice or FXR-KO mice were fasted for 10 h and treated with vehicle 
or GW4064 (30 mg/kg, i.p.) for 6 h, and livers were collected for ChIP, CoIP, q-RTPCR, nuclear 
localization, and imaging studies. For in vivo autophagy studies, WT or FXR-KO mice were 
injected with Ad-GFP-LC3, and 1 week later, livers were collected for confocal microscopy. For 
EM studies, liver samples were stained with uranyl acetate/lead citrate and then imaged by TEM 
(EM902A; Carl Zeiss). All animal use and adenoviral procedures were approved by the 
Institutional Animal Care and Use and Biosafety Committees. Primary mouse hepatocytes or 
Hepa1c1c7 cells were incubated with HBSS (1 h) to mimic starvation or incubated with 
complete media and treated with vehicle, GW4064 (100 nM), rapamycin (100 nM), Torin (1 
µM), chloroquine (50 µM), or bafilomycin A1 (100 nM) for the indicated times. For siRNA 
experiments, cells were treated with 5-20 nM of siRNA for 48-72 h. Lipophagy and glycophagy 
were detected by co-staining of autophagic LC3 with BODIPY 581/591 (D-3861, Life 
technologies) lipid staining and glycogen staining with 2-NBDG, a fluorescence glucose 
derivative (N13195, Life technology). For luciferase assays, a DNA fragment from the Atg7 and 
Tfeb genes that contains both FXR and CREB binding sites was cloned into the pGL3-Luc 
vector (Promega, Inc.). In gel shift assays, an oligonucleotide from the Atg7 gene was γP32-
labeled and incubated with purified CREB, FXR, and TNT-synthesized CRTC2, as previously 
described (41). For analyses of ChIP-seq, published mouse liver data for FXR (12, 13) and 
CREB (15, 33) were used. ChIP-seq reads were mapped to the mouse genome (mm9) by Bowtie. 
Autophagy genes were identified that had FXR and CREB peaks within 10 kb from the TSS 
from a total 230 autophagy-related genes.  De novo motif analysis was done within 100 bp 
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centered at the FXR peaks using the web tool STAMP and p-values were calculated by 
hypergeometric test.  
 
3.2 Materials and Reagents 
Antibodies for FXR (sc-13063), CREB (sc-186), CRTC2 (sc-46272, sc-271912), RNA 
pol II (sc-9001), NcoR (sc-8994), SMRT (sc-1612), p300 (sc-584), PGC-1α (sc-13067), H3K27-
me2 (Abcam 050851), H3K4-me2 (Abcam 8580), ubiquitin (sc-9133), lamin A (sc-20680), β-
tubulin (sc-5274), and actin (sc-1616) were purchased from Santa Cruz Biotechnology. 
Antibodies for p(S133)-CREB (#9198S), LC3 (#4108), p62 (#5114), S6 kinase (#9202), p-S6 
kinase (#9208), and ATG7 (#2631), from Cell Signaling. Antibody for p (S171)-CRTC2 (bs-
3415R) was purchased from Bioss USA. Mouse CREB siRNA was purchased from Thermo 
Scientific, FXR siRNA and control siRNA from Dharmacon, and Atg7 siRNA from Life 
Technologies (AM16708).  
 
3.3 In vivo experiments 
For FXR activation assay, 10-12 week old male FXR-KO (Jackson lab) or WT C57BL/6J 
mice were fasted for 10 h and then i.p. injected with GW4064 (30 mg/kg) for 6 h or fed normal 
chow or 0.5% cholic acid (CA)-supplemented chow for 6 h. For adenoviral experiments, Ad-
GFP-LC3 (0.5-1x10
9
 active particles/mouse in 200 µl PBS) was injected via tail vein into FXR-
KO or WT mice. After 1 week, the mice were fasted overnight and livers were collected. The 
frozen or paraffin-embedded liver sections were prepared for staining.  
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3.4 Liver transmission electron microscopy 
         Mouse liver was fixed using Karnovsky’s fixative solution [1% paraformaldehyde, 2% 
glutaraldehyde, 2 mM CaCl2, and 100 mM sodium cacodylate (pH 7.4)] for 2 h and washed with 
100 mM sodium cacodylate (pH 7.4). After post-fixing with 1% osmium tetroxide and 1.5% 
potassium ferrocyanide for 1 h, mice livers were dehydrated with 50-100% alcohol and stained 
en bloc with 0.5% uranyl acetate. The liver tissues were embedded in Poly/Bed 812 resin 
(Pelco), polymerized, and sectioned using a Reichert Jung Ultracut Smicrotome (Leica, 
Wetzetlar) and stained with uranyl acetate and lead citrate. The liver tissue was imaged by 
transmission electron microscopy (EM902A; Carl Zeiss).  
 
3.5 Fluorescent Detection of Lipophagy and Glycophagy 
        Hepac1c1 cells were cultured in 6-well plates in complete medium reaching 80% 
confluency, then transfected with siRNAs (siFXR, siAtg7, siCREB, siTFEB, siCtl) and plasmids 
(GFP-LC3, CREB overexpression plasmid). After 36 h, cells were supplemented with 400 um 
Oleate acid (O3008, Sigma) for 6hr prior to 3-6 h HBSS fasting. Cells were fixed with 4% 
paraformaldehyde (#28908, Thermo scientific), then washed with PBS couple of times, Final 
concentration of 1 µg/ml of BODIPY 581/591 (D-3861, Life technologies) in 150 mM NaCl 
were used to staining lipid droplets for 10 mins at room temperature, protected from ambient 
light. Then washed cells couple of times with PBS, counterstain with DAPI. For detection of 
glycophagy, Hepac1c1 cells were cultured in complete medium (with 4.5g/L D-Glucose), then 
transfected with same siRNAs, plasmids and mRFP-LC3 as above.  Cells were fasted with 
DMEM glucose-free medium for 3 h and then incubated with DMEM medium containing 5 mM 
glucose and 5 ng/mL 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
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Deoxyglucose, a fluorescence glucose derivative, which can be used to view and monitor the 
breakdown of glycogen) (N13195, Life technology) for 24 h, then fasted with HBSS for 3-6 h. 
Nuclei were counterstained with DAPI and imaged by confocal microscopy (Zeiss, LSM700). 
 
3.6 Histology and Immunohistochemistry 
         Hepa1c1c7 cells were cultured and transfected with GFP-LC3 plasmid or together with 5-
20 nM of siRNA (siFXR, siCREB, siAtg7, siTFEB or siCtl) for 24-48 h. For GW 4064 
experiments, cells were treated with vehicle or 1 µM GW4064 overnight. To mimic starvation 
studies, cells were incubated in either complete media or serum free media for 24 h followed by 
1 h in HBSS. For in vivo detection of hepatic autophagy, frozen or paraffin-embedded liver 
samples injected with Ad-GFP-LC3 were fixed with 4% paraformaldehyde and counterstained 
nuclei with DAPI and images were taken by confocal microscopy and analyzed by ZEN software 
(Zeiss LSM700). Quantitation of GFP-LC3 puncta in vitro or in vivo were calculated by 
averaging the puncta numbers in 30 cells per group. For checking endogenous FXR and CRTC2 
localization, paraffin-embedded liver slides were incubated with their primary antibody for 2 h 
and with secondary antibody, Alexa 647 goat anti-mouse or anti-rabbit IgG for 1 h. Nuclei were 
labeled with DAPI and images were taken and analyzed by confocal microscopy (Zeiss, 
LSM700). 
 
3.7 Biochemical localization study 
         Mice (pooled from 3 WT and FXR-KO mice) were fasted or fed overnight and liver 
tissues were minced, resuspended in hypotonic buffer, and lysed by homogenization. After 
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centrifugation, nuclear pellets and the cytoplasmic supernatant were collected. Cytoplasmic β-
tubulin and nuclear lamin A were detected as controls for the quality of cellular fractionation.  
 
3.8 Liver ChIP and sequential re-ChIP 
         Livers from WT or FXR-KO mice were minced and incubated in PBS containing 1% 
formaldehyde for 10 min, and glycine (125 mM) was added. Minced liver was resuspended in 
hypotonic buffer and lysed by homogenization. Nuclei were pelleted, resuspended and sonicated, 
and chromatin was IPed using 1-1.5 µg of antibody. For re-ChIP assays, CREB was IPed first 
and chromatin was eluted by adding 50 µl of 10 mM DTT at 37
o
C for 30 min. Then, the 
chromatin samples were diluted (20-fold) with 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM 
EDTA, and 1% Triton X-100 and then re-IPed. The immunoprecipitates were extensively 
washed, chromatin was eluted, and the amounts of genomic DNA from selected genes were 
determined by semi-q PCR and q-PCR (primer sequences in Table S6). For ChIP combined with 
siRNA treatment, primary mouse hepatocytes were treated with siRNA for CREB (5 nM) and 36 
h later, cells were treated with vehicle or GW4064 for 6 h and ChIP assays were performed. 
Primary hepatocytes were isolated by collagenase (0.8 mg/ml, Sigma-Aldrich Co.) perfusion 
through the portal vein of mice anesthetized with isoflurane as recently described (42).  
 
3.9 Tfeb-luc and Atg7-luc construction and luciferase assay 
         DNA fragments near the Tfeb gene (ch17 47907235-47908235) and the Atg7 gene (Chr6: 
114772715-114773373) that contained FXR peaks were amplified by PCR from mouse genomic 
DNA and cloned into the PGL3-SV40-Luc vector at the Kpn1/Nhe1 site and SacI/BglII site, 
respectively, and the cloning was confirmed by sequencing. A FXR mutant was constructed by 
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mutation at the first zinc finger in the DNA binding domain. Luciferase assays were performed 
in Hepa1c1c7 cells. The values for luciferase activities were normalized to β-gal activities. 
 
3.10 CoIP, GST-pull down, and q-RTPCR 
         Whole liver extracts from WT mice were prepared and CoIP protein interaction studies 
were performed as previously described (41). The pGEX4T1-FXR domains containing the AF1, 
DBD, or LBD domains were constructed by PCR. The PCR product was inserted into the 
pGEX4T-1 vector at BamH1 and Xho1 sites. GST-FXR fusion proteins were expressed in E. coli 
BL21/DE3 and purified, CREB was synthesized in vitro, and GST-pull down assays were 
performed. For q-RTPCR, total RNA was isolated, cDNA was synthesized, and q-RTPCR 
(primer sequences in Appendix, Table.C7) was performed with an iCycler iQ (Bio-Rad). The 
amount of mRNA was normalized to that of 36B4.  
 
3.11 In vitro gel mobility shift assays 
         Gel mobility shift assays were performed as previously described (41). Briefly, double 
stranded oligonucleotides (32 mers) that contain the CREB binding peak from the Atg7 gene 
were labeled with [γ-32P] ATP and incubated with purified CREB and FXR and with CRTC2 
synthesized by in vitro transcription and translation (TNT) (Promega, Inc), in the presence of 100 
ng poly dIdC and 20 µg BSA. Binding reactions were analyzed by electrophoresis in 6% non-
denaturing polyacrylamide gels in a low ionic Tris-acetate buffer with circulation.  
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3.12 ChIP-seq data analyses for FXR and CREB 
         We analyzed published ChIP-seq data for FXR (12, 13) and CREB (15, 33) (GSE45674, 
from GEO). ChIP-seq reads were uniquely mapped to the mouse reference genome (mm9) by 
Bowtie. Ultrafast and memory-efficient alignment of short DNA sequences to the human 
genome (http://bowtie-bio.sourceforge.net/index.shtml,) with at most 2 mismatches. MACS was 
used to find ChIP-seq peaks with default parameters. Autophagy genes contained FXR binding 
peaks within 10 kb of the TSS were considered potential FXR target genes. Similar, genes 
contained CREB binding peaks within 10 kb of the TSS were considered potential CREB target 
genes. Genes were considered to have shared FXR-CREB binding peaks if the distance between 
the midpoints of the FXR and CREB binding peaks was less than 500 bp. To identify CREB 
binding motifs on those 78 shared autophagy genes, FIMO was used to search for two CREB 
motifs within 500 bp of the midpoints between the centers of the overlapping FXR and CREB 
peaks using position weight matrices (PWM), MA0018.1 and MA0018.2, from JASPAR with P 
< 0.001.   
 
3.13 Identification of transcription factor motifs within FXR binding peak regions 
         For the de novo analysis of DNA binding motifs within the FXR binding peaks, the 36 
motifs with the least motif score, 1.19, were identified using the Gibbs sampling method, with a 
maximum motif length set to 30bp. 50,000 iterations for Markov chain Monte Carlo were used, 
the top 36 motifs were chosen for transcriptional factor identification. Motif similarity was 
analyzed using the on-line STAMP tools (http://www.benoslab.pitt. edu/stamp/). 
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4. Results 
4.1 Pharmacological activation of FXR transcriptionally inhibits hepatic autophagy         
         In analyses of mouse liver ChIP-seq data (12, 13), intriguingly, FXR binding peaks were 
detected within 10 kb of the transcription start sites (TSS) in 178 of 230 autophagy-related genes 
(Appendix, Table.C1) in the Human Autophagy Database (website:autophagy.lu). These genes 
are involved in key processes of autophagy, such as autophagy induction, autophagosome 
elongation, autolysosome formation, lysosomal function, and also regulation of autophagy gene 
expression.  FXR binding peaks near selected autophagy-related genes are displayed in 
Appendix, Fig. D1. These findings suggest that FXR may directly repress transcriptional 
program of hepatic autophagy. To confirm the ChIP-seq results, liver ChIP analysis was 
performed. FXR transcriptional signaling was activated by its specific agonist GW4064 because 
the natural FXR agonists, bile acids, activate multiple other signaling pathways including the 
membrane bile acid receptor TGR5 (27, 28). Treatment with GW4064 in fasted mice increased 
FXR occupancy at many autophagy genes as well as at the known FXR-target gene Shp in WT 
mice (Fig. 18A), but not in FXR-knockout (KO) mice (Appendix, Fig. C2). The mRNA levels of 
most of these genes were significantly decreased by GW4064 treatment in WT mice (Fig. 18B), 
but not in FXR-KO mice (Appendix, Fig. C3). GW4064 treatment also decreased their pre-
mRNA levels (Appendix, Fig. C4). These findings indicate that activation of FXR increased its 
occupancy at many autophagy genes and repressed their expression. 
         We next tested whether the inhibition of autophagy genes by pharmacological activation 
of FXR leads to suppression of macroautophagy using electron microscopic analysis. More 
autophagic vesicles in mouse liver were detected in fasted mice compared to fed mice, but the 
increase was significantly blunted by GW4064 treatment (Fig. 18C). Mitochondria in double 
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membrane autophagosomes or autolysosomes, known as mitophagy, were detected in fasted WT 
mice but not after GW4064 treatment (Fig. 18C). The effects of FXR activation on levels of LC3 
and p62 were also examined. LC3-II, LC3 conjugated with phosphatidylethanolamine upon 
induction of autophagy, is present on autophagosome membranes and thus, LC3-II abundance is 
an indicator of autophagic flux (29, 30). Conversely, the autophagosome adaptor protein 
p62/SQSTM1 is degraded by autophagy and thus, p62 accumulates when autophagy is inhibited  
(29, 30). Treatment with GW4064 decreased LC3-II and increased p62 levels in liver extracts 
from WT mice (Fig. 18D) and decreased LC3II levels were still observed in hepatocytes after 
treatment with lysosomal inhibitors, chloroquine (Fig. 18E) or bafilomycin A1 (Fig. 18F, 
Appendix, Fig. C5). The GW4064 effects on inhibition of LC3-II levels were detected by 1 h and 
substantially decreased by 4-6 h treatment with GW4064 (Fig. 18F). These results indicate that 
FXR inhibits autophagy by transcriptionally repressing autophagy components, and these effects 
are likely independent of lysosomal function.   
         Activation of FXR signaling in vivo results in secretion of the intestinal FGF19 that acts 
at the liver (31), and could lead to confounding effects of FXR on hepatic autophagy. Thus, the 
direct FXR effects on autophagy were also examined in Hepa1c1c7 cells by measuring punctuate 
GFP-LC3, a marker of autophagy (29, 30). GFP-LC3 puncta were increased by incubation in 
HBSS starvation media, but this increase was attenuated by GW4064 treatment and the 
attenuation was not detected by downregulation of FXR (Fig. 18G). These findings indicate that 
FXR directly inhibits autophagy, which is consistent with the repression of autophagy genes by 
FXR.  
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4.2 FXR is a physiological repressor of hepatic autophagy in the fed state.  
         Since FXR is activated after feeding by bile acids, we tested whether FXR acts as an in 
vivo physiological repressor of autophagy by examining the effects of feeding and fasting on 
punctate fluorescence of adenoviral-expressed GFP-LC3 in WT and FXR-KO mice. GFP-LC3 
puncta were substantially decreased after feeding in WT mice, indicating inhibition of hepatic 
autophagy, but this decrease was markedly attenuated in FXR-KO mice (Fig. 19A, Appendix, 
Fig. C6), suggesting that FXR is required for full inhibition of autophagy after feeding. In 
biochemical analysis, feeding resulted in decreased LC3-II levels and increased p62 levels in WT 
mice, but not in FXR-KO mice (Fig. 19B). These findings indicate that FXR acts as a key 
physiological repressor of autophagy in the fed-state.  
         In response to feeding, autophagy components are acutely suppressed by insulin/growth 
factor signaling through the mTOR/S6 kinase pathway (7, 32). We, therefore, tested if autophagy 
inhibition by FXR in the fed state is directly associated with activation of the mTOR pathway.  
Activation of FXR by GW4064 treatment in starvation media or downregulation of FXR by 
siRNA in complete media resulted in expected changes in LC3-II levels, but no changes in 
phosphorylated S6 (p-S6) levels in hepatocytes (Fig. 19C). Similar effects were observed in liver 
extracts of mice treated with GW4064 (Fig. 19D). Further, treatment with rapamycin, an 
inhibitor of mTOR, increased GFP-LC3 puncta and LC3-II levels as expected, and GW4064 
treatment decreased LC3-II levels without changing the p-S6 levels (Fig. 19E, Appendix, Fig. 
C7). These results, together with the in vivo studies above, suggest that FXR-mediated inhibition 
of autophagy is largely independent of activation of mTOR pathway and likely results from 
decreased autophagic flux due to the transcriptional inhibition of autophagy genes.  
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4.3 CREB is a new transcriptional activator of autophagy and CREB and FXR oppositely 
regulate lipophagy and glycophagy 
         To understand how FXR inhibits autophagy genes, we analyzed DNA binding motifs for 
transcription factors present within FXR binding peak regions detected by ChIP-seq in mouse 
liver (12). In motif analysis of common sequences present in FXR peak regions, IR1 DNA 
binding motifs for FXR (24-26) were not detected, but instead, binding sites for transcription 
factors, including CREB, FOXOs, PPAR, AP1, and C/EBP, were detected (Appendix, Table C2). 
Of most interest, DNA binding motifs, TGACGT(C/T)(A/T), for CREB, a key transcriptional 
activator driving fasting metabolic responses (10, 11), were identified as the top-scoring sites 
(Fig. 20A, Appendix, Fig. C8). Remarkably, by comparing published liver ChIP-seq studies for 
CREB (15, 33) with FXR ChIP-seq data (12, 13), CREB binding peaks were detected at 112 of 
230 autophagy-related genes (Appendix, Table C3) and these peaks overlapped with FXR peaks 
in 78 genes (Fig. 20B, Appendix, Table C4). Notably, the overlapping peaks were found within 1 
kb of the TSS in most cases (Appendix, Table C3), which is consistent with recent findings that a 
majority of global functional CREB sites are present in the promoter regions (15, 34). Selective 
autophagy-related genes showing shared binding sites of FXR and CREB are listed in Fig. 20C 
and displayed in Appendix, Fig. C9, and co-occupancy of FXR with CREB at selected genes was 
confirmed in re-ChIP assays (Appendix, Fig. C10). These studies suggest that both CREB and 
FXR may coordinately regulate the autophagy transcriptional circuit. Supporting this idea, 
downregulation of CREB substantially decreased expression of autophagy genes (Fig. 20D) and 
reduced the number of LC3-II GFP puncta (Fig. 20D) in hepatic cells under nutrient-deprived 
conditions. These results suggest that CREB is a novel activator of many autophagy genes and 
that FXR may antagonize the CREB activity.  
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         We next determined the role of CREB and FXR in linking autophagy and lipid 
metabolism by examining autophagic degradation of lipids, known as lipophagy. Fluorescent co-
staining of LC3 puncta with BODIPY lipid staining showed that lipophagy was detected in 
fasted hepatic cells and that downregulation of CREB1 by siRNA reduced it (Fig. 20F, left). 
Further, downregulation of Atg7 blocked autophagy (Appendix, Fig. C11, a-c) also inhibited 
lipophagy and overexpression of CREB reversed the inhibition (Fig. 20F, right), suggesting that 
CREB promoted lipophagy under nutrient-deprived conditions. In contrast, downregulation of 
FXR by siRNA increased co-staining of LC3 with BODIPY staining in complete media (Fig. 
20G, left) and activation of FXR by GW4064 treatment decreased this response in fasted cells 
(Fig. 20G, right), suggesting that FXR inhibited lipophagy under nutrient-rich conditions. 
Similar results happened on glycophagy (autophagic degradation of glycogen). PAS staining 
showed that downregulation of CREB or Atg7 by siCREB or siAtg7 prevent the breakdown of 
glycogen in the fasting state (Appendix, Fig.C12a). Moreover, Fluorescence co-detection of 
glycogen (2-NBDG) and autophagy (mRFP-LC3) showed that downregulation of CREB or Atg7 
(siCREB or siAtg7) prevent the glycophagy occurrence in fasted Hepa1c1c7 cells, however 
overexpression of CREB in autophagy-deficient cells promotes glycophagy reoccurrence in 
fasting state (Appendix, Fig.C12b). Downregulation of FXR by siRNA promotes glycophagy 
and activation of FXR by GW4064 treatment prevents glycophagy in hepatic cells (Appendix, 
Fig.C12, c-d). These results suggest that CREB and FXR oppositely regulate lipophagy and 
glycophagy responses by different nutrient status.  
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4.4 Agonist-activated FXR trans-represses autophagy genes by disrupting the 
CREB/CRTC2 complex 
         Next, we investigated mechanisms of how FXR and CREB regulate autophagy genes.  
An Atg7 or Tfeb DNA fragment that contained both FXR and CREB peaks was inserted into a 
luciferase vector. Overexpression of CREB and its coactivator CRTC2 (10) increased the 
luciferase activity and overexpression of FXR inhibited the activity (Fig. 21A). However, FXR 
inhibition was lost when the CREB site was mutated (Appendix, Fig. C13a) or CREB was 
downregulated by siRNA (Appendix, Fig. C13b). Notably, Tfeb-luc activity increased by the 
CREB/CRTC2 was attenuated by FXR, but not by other liver-abundant nuclear receptors, LRH-1, 
HNF-4, or CAR (Appendix, Fig. C14). Further, in CoIP, the CREB/CRTC2 interaction in fasting 
was abolished by GW4064 treatment, whereas CREB interaction with FXR was increased 
(Appendix, Fig. C15). In GST-pull down, CREB directly interacted with the C-terminal domain 
of FXR (Fig. 21B, Appendix, Fig. C16). Consistent with these results, a DNA binding-deficient 
FXR mutant (Appendix, Fig.C21c) failed to activate FXRE-luc activity but still repressed Tfeb-
luc activity (Fig. 21C). Together, these results suggest that FXR may trans-represses autophagy 
genes by suppressing CREB activity. 
         We further examined the functional interactions of FXR and CREB/CRTC2 complex 
formed at autophagy genes by ChIP assay. GW4064 treatment did not change the occupancy of 
CREB but decreased that of CRTC2, while FXR occupancy was increased and RXRα occupancy 
was not markedly detected (Appendix, Fig. C17). Notably, downregulation of CREB decreased 
FXR occupancy at Ulk1, Atg7, and Tfeb genes, suggesting CREB is important for FXR 
recruitment (Appendix, Fig. C18). Feeding mice with cholic acid chow also showed similar 
effects on occupancy of CREB, CRTC2, and FXR (Appendix, Fig. C19). In re-ChIP, GW4064 
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treatment substantially decreased the occupancy of CRTC2 and increased FXR occupancy in WT 
mice, but not in FXR-KO mice (Fig. 21D, Appendix, Fig. C20). In gel shift assays with a DNA 
fragment from Atg7 as probe, addition of increasing FXR with CRTC2 resulted in the 
dissociation of the CREB/CRTC2 complex and formation of the CREB/FXR (Fig. 21E, 
Appendix, Fig. C21), indicating that FXR competes with CRTC2 for binding to the CREB/DNA 
complex. Remarkably, GW4064 treatment was required for the FXR-mediated effects (Fig. 21F). 
Association of FXR at the Atg7 promoter correlated with increased gene-repressing and 
decreased gene-activating histone marks (Fig. 21G) and increased occupancy of HDAC3-
containing corepressors, NcoR and SMRT (Appendix, Fig. C22), indicating formation of a 
repressive transcriptional complex and similar results were observed at Ulk1 and Tfeb genes 
(Appendix, Fig. C23). Together, these results demonstrated that agonist-activated FXR trans-
repressed autophagy genes by disrupting the functional CREB/CRTC2 complex.  
         The disruption of the CREB/CRTC2 complex by GW4064 suggests that physiological 
activation of FXR by bile acids upon feeding may displace CRTC2 from the CREB complex.  
Consistent with findings that feeding/fasting affect the cellular location of CRTC2 (10), CRTC2 
was present in the nucleus in fasted animals and largely excluded from the nucleus in fed WT 
mice, but in fed FXR-KO mice, these effects were attenuated (Fig. 21H, Appendix, Fig. C23a). 
In contrast, FXR was found in both nucleus and cytoplasm during fasting; and feeding or 
GW4064 treatment markedly increased the nuclear abundance of FXR (Appendix, Fig. C23, b-
c). Fasting increases CREB and CRTC2 activity through their phosphorylation and 
dephosphorylation, respectively (10, 35). Indeed, p-CREB was detected in the nucleus in the 
fasted liver, whereas p-CRTC2 (S171) and CRTC2 was detected in the cytoplasm of the fed 
liver, but the feeding-induced cytoplasmic localization of p-CRTC2 (S171) and CRTC2 was 
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partially reversed in FXR-KO mice (Fig. 21I). Under these fasting conditions, activated p-PKA 
levels were increased, whereas p-PKB levels were not detectable, and p-AMPK levels were not 
markedly changed (Appendix, Fig. C24). Importantly, GW4064 inhibition of Atg7 and Tfeb was 
largely abolished with a p-defective CRTC2 S171A mutant that is constitutively retained in the 
nucleus (Appendix, Fig. C25). These results indicate that activation of FXR disrupted the 
CREB/CRTC2 complex, resulting in decreased nuclear CRTC2 levels.  
         In re-ChIP assays, occupancy of CRTC2 in the CREB-bound autophagy genes was 
substantially decreased in fed mice, while FXR occupancy was increased (Fig. 21J). In contrast, 
in FXR-KO mice, the feeding-mediated effects were reversed, but only partially. The mRNA and 
pre-mRNA levels of these autophagy genes were reduced after feeding in WT mice, and the 
reduction was partially or fully blocked in FXR-KO mice (Appendix, Fig. C26). These partial 
effects in FXR-KO mice suggest that other meal-related signals also contribute to autophagy 
gene regulation. Indeed, treatment with insulin, FGF19, or GW4064 downregulated autophagy 
genes to different extents, in a gene-specific manner (Appendix, Fig. C27). Together, these 
findings reveal that one mechanism by which agonist-activated FXR inhibits hepatic autophagy 
is the trans-repression of autophagy genes by disrupting the functional CREB/CRTC2 complex.  
 
5. Discussion 
The present study identifies FXR and CREB as novel transcriptional regulators of the 
hepatic autophagy gene network (Fig. 21K). Under nutrient-deprived fasting, the 
CREB1/CRTC2 complex activates transcription of many autophagy-related genes involved in 
autophagy processes, lysosomal functions, autophagy effectors, and autophagy gene regulators. 
Upon feeding, FXR activated by bile acids (mimicked by GW4064) directly interacts with CREB 
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and disrupts the CREB/CRTC2 complex, which results in decreased nuclear CRTC2 levels, 
formation of a repressive transcriptional complex, and inhibition of many autophagy-related 
genes. Mechanistic studies utilizing molecular, biochemical, imaging, and functional analyses, 
support our conclusions. Remarkably, both FXR and CREB transcriptionally regulate TFEB, a 
key activator of autophagy/lysosomal gene networks (17, 18), which should contribute to 
effective regulation of autophagy gene program in response to nutrient status. Notably, some 
autophagy genes appear to be regulated predominantly by CREB or TFEB, while others 
regulated by both (Appendix, Fig. C28).  
         In addition to CREB, other nutrient-sensing regulators are likely important for 
transcriptional activation of autophagy. One example is the nuclear receptor PPARα as reported 
in the accompanying manuscript. More than 200 autophagy-related genes are known, so it is not 
surprising that FXR represses autophagy by multiple mechanisms depending on the genes and 
context of the DNA. In some genes, FXR may trans-repress by disrupting the CREB/CRTC2 
complex, whereas inhibit others by competing with PPARα for DNA binding, or it is even 
possible that both mechanisms are detected in the same gene. It is also possible that CREB 
activated by PKA is important early in fasting and PPARα sensing elevated fatty acid levels is 
more important after prolonged fasting, so that after refeeding, the FXR/CREB interaction is 
dominant after a short fast and the FXR/PPARα interaction is more important after a prolonged 
fast. Supporting this idea, occupancy of CRTC2 and PGC-1α, coactivators of CREB and PPARα, 
was detected at different regions of Atg7 and Lc3a genes, fasting time-dependent manner 
(Appendix, Fig. C29). Also, only a fraction (78 of 178) of FXR target autophagy genes had 
shared FXR/CREB binding, which further supports the possibility of multiple FXR mechanisms. 
104 
 
         There is increasing evidence for a functional role of autophagy in regulating catabolic 
pathways of cellular nutrients (18, 36). In addition to effects on autophagy identified in the 
present study, FXR (24, 37) and CREB (10, 11, 38) are well-known transcriptional regulators of 
lipid and glucose metabolism. We observed that expression of glucose and lipid metabolic genes 
regulated by CREB and FXR was substantially altered in Atg7-depleted autophagy-deficient 
cells (Appendix, Fig. C29). Intriguingly, CREB activated autophagic degradation of lipid 
droplets, or lipophagy, under nutrient-deprived conditions, while FXR inhibited this response, 
suggesting the novel function of CREB and FXR in linking autophagy and lipid catabolic 
process. Future studies will be required to establish the in vivo role of the FXR/CREB axis in 
linking autophagy and cellular nutrient/energy metabolism by different nutrient status.  
         Autophagy has been known to be crucial for cellular survival under extremely stressful 
conditions but the present study indicates that hepatic autophagy occurs under normal 
physiological conditions and is dynamically regulated by FXR and CREB during feeding/fasting 
cycles. While nutrient-sensing kinases rapidly modulate activity and/or stability of autophagy 
components, transcriptional regulations by the FXR/CREB axis are slower and delayed 
responses, which should effectively sustain autophagy repression or activation. Defective 
autophagy has been implicated in many human diseases but excess autophagy promotes cell 
death (3, 39, 40). In this regard, the nutrient-sensing FXR/CREB axis that tightly regulates the 
autophagy gene network may present new molecular targets for treating diseases associated with 
autophagy dysfunction, including metabolic disorders, neurodegenerative disease, and cancer. 
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Chapter Five 
 Coordination of Gut-liver FGF19 Signaling by the Bile Acid 
Nuclear Receptor FXR 
1. Abstract 
 Hepatic metabolic responses to a meal are regulated by an intricate interplay among 
intestinal, pancreatic and hepatic hormones and factors. The nuclear receptor, FXR, functions as 
the primary biosensor for bile acids and plays a crucial role in maintaining bile acid, glucose, and 
lipid hemostasis. After a meal, intestinal FXR is activated by bile acids and induces the 
expression and secretion of FGF19. FGF19 then travels in the bloodstream to the liver and binds 
to its hepatic membrane receptor complex, FGFR4 and βKL. Thus, FGF19 signaling is activated 
and genes downstream of FGF19 signaling that are involved in bile acid, glucose, and lipid 
metabolic pathways together mediate post-prandial responses. Previous genome-wide analysis of 
hepatic FXR Chip-seq data by our laboratory revealed binding sites for FXR on FGF19-activated 
Erk signaling component genes, especially βKL. Furthermore, my preliminary data shows that 
FXR occupancy and expression of βKL are increased after treatment with GW4064. In addition, 
the expression of βKL is sharply decreased and FGF19 signaling is potentially impaired in FXR-
null mice. Further, the FXR-RXRα complex directly binds to βKL gene fragments in vitro gel 
shift assays and expression of a βKL-luciferase promoter is induced by treatment with GW4064 
in cells. My initial in vivo experiments show that FXR regulates FGF19 synthesis in intestine 
earlier than FXR induces the synthesis of genes in Erk signaling pathway, particularly βKL, in 
the liver. More interestingly, FGF19 appears to down-regulate βKL expression at even later 
114 
 
times, which suggesting FGF19 signaling may potentially function to feedback inhibit βKL 
synthesis in liver. Future studies will be needed to definitively test this hypothesis.   
 
2. Introduction 
 Metabolic disorders, such as obesity, type 2 diabetes, and fatty liver disease, are caused 
by abnormally regulation of bile acid, cholesterol, lipid and glucose levels (1). The role of 
pancreatic and intestinal hormones, such as insulin, glucagon and glucagon-like peptide, have 
been well studied for decades, but recently identified and less understood is the importance of 
bile acids as a fed-state hormone. Bile acids were originally thought to simply facilitate digestion 
and absorption of lipid-soluble nutrients, but have emerged recently as critical integrative 
signaling molecules that control metabolism and energy balance (2-3).  
          Farnesoid X Receptor (FXR) is a member of the nuclear receptor (NR) superfamily. 
Nuclear receptors are usually activated by binding lipophilic ligands and transduce signals that 
facilitate or inhibit the transcription of target genes. FXR functions as the primary biosensor for 
bile acids. As a transcriptional factor, FXR regulates the expression of numerous genes involved 
in bile acid, cholesterol, triglyceride and glucose metabolism (13). Upon activation by bile acids 
or its synthetic agonist GW4064, FXR forms a requisite heterodimer with RXRα (retinoid X 
receptor-) and binds to FXR response elements (FXRE) of target genes. In addition to inducing 
gene expression directly, the FXR/RXR heterodimer indirectly inhibits some target genes by 
induction of an orphan nuclear nuclear receptor and transcriptional corepressor, small 
heterodimer partner (SHP) (14, 15). The role of the induction of SHP by FXR in maintaining bile 
acid hemostasis has been well established. 
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 Another pathway by which FXR regulates bile acid synthesis is through the induction of 
FGF19 from intestine. Normally, bile acid is synthesized and stored in gallbladder. After a meal, 
bile acid is released from gallbladder and flows into the intestine. Bile acid-activated intestinal 
FXR which then induces the synthesis of FGF19 in the intestine. The secreted FGF19 travels 
through the enterohepatic circulation and binds to its hepatic cell membrane receptor complex, 
FGFR4, a tyrosine kinase receptor, its co-receptor, βKL. Then, it triggers FGF19 downstream 
signaling cascades involved in regulating fed-state metabolism (7, 8). FGF19-activated Erk 
signaling has already been reported to have multiple metabolic functions. First, bile acid 
synthesis is inhibited and protein/glycogen synthesis is stimulated during the late fed-state period 
(9). In addition, FGF19 inhibits hepatic glucose synthesis by inhibiting the CREB-PGC1α 
regulatory pathway (10). βKL, as membrane co-receptor, is a key component for mediating 
FGF19 signaling.  βKL-null mice exhibit disrupted bile acid and glucose hemostasis, which 
suggests that βKL is a key regulatory component in these processes (11). This FGF19-βKL axis 
is, therefore, important for the coordinated gut-liver metabolic response in the fed-state (12). 
Since FXR induces FGF19 expression in the intestine, but also induces gene expression of SHP 
and other genes in the intestine, it is possible that FXR may enhance FGF19 signaling through 
transcriptional regulation in the liver but this possibility has not been tested (17).   
A previous genome-wide analysis of hepatic FXR binding sites by our laboratory (18) 
revealed that the binding sites for FXR were detected near pathway component genes, especially 
βKL, of Erk which is activated by FGF19. In this study, I will test the novel concept that FXR 
not only induces synthesis and secretion of intestinal FGF19, but also primes the liver for FGF19 
signaling by regulating expression of FGF19 signaling pathway genes, particularly βKL. These 
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studies will provide a more comprehensive understanding of the role of FXR in coordinating gut-
liver metabolic homeostasis.  
 
3. Materials and Methods 
3.1 Reagents and Materials 
SiRNA for βKL (s96291, s96292) were purchased from Applied Biosystems. Antibodies 
to βKL for IP and IB (AF2619) were purchased from R&D systems. Antibodies to FXR (sc-121) 
and tubulin (sc-8085) were purchased from Santa Cruz Biotech and antibodies for p-Erk (#9101) 
and t-Erk (#4695) were purchased from Cell Signaling Technology. 
 
3.2 Animals 
Balb/c mice were fed normal chow or high fat chow (42% fat, Research Diet) ad libitum 
for 4-5 months to induce obesity. To activate hepatic FXR, GW4064 (30 mg/kg body weight) in 
100 l of corn oil (Sigma) or vehicle (100 l corn oil) was injected intraperitoneally 1 h before 
sacrifice. Mouse livers were removed and used for the ChIP assays. The levels of Shp mRNA 
were measured by q-RTPCR to monitor activation of FXR in liver.  
 
3.3 Construction of Luciferase plasmids 
Various lengths of βKL fragments containing the potential binding sites of FXR based on 
ChIP-seq and NubiScan and NHRScan analysis (18) were cloned into pGL3 basic luciferase 
plasmids (Promega). The potential FXRE site was mutated by QuickChange II Site-
Directed Mutagenesis Kit (Agilent Technologies). All positive clones were identified by DNA 
sequencing (UIUC sequencing center).  
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3.4 Luciferase assay 
The luciferase plasmids, β-galactosidase (as transfection efficiency control), FXR, and 
RXR expression plasmids were transfected into Cos-1 cells for 24 to 36 h. The cells were treated 
for 3 to 4 h with GW4064 before harvesting the cells. Luciferase activities were assayed as 
described before. 
 
3.5 Isolation of mouse primary hepatocytes  
Hepatocytes were isolated by collagenase type IV (0.8 mg/ml, C5138, Sigma-Aldrich Co.) 
perfusion through the portal vein of mice anesthetized with isoflurane. The cell suspension was 
filtered through a cell strainer (100 µm nylon, BD) and cells were washed with M199 medium 
(cat#11150, Invitrogen). Hepatocytes were resuspended in M199 medium and centrifuged 
through 45% Percoll (Invitrogen) in M199 medium. The cells were plated in M199 medium 
containing FBS (Invitrogen) and P/S (Sigma) antibiotics.  
 
3.6 Chromatin immunoprecipitation (ChIP)  
To determine binding sites for target proteins of interest, ChIP assays were performed. 
Briefly, livers from mice treated with GW4064 or vehicle were collected in PBS, finely minced 
with a razor blade, and then cross-linked by incubation with 1% formaldehyde in PBS at room 
temperature for 10 min. Cross-linking was stopped by adding 125 mM glycine followed by 
washing the samples twice with ice-cold PBS. The tissue samples were resuspended in hypotonic 
buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2% NP40, 0.15 mM spermine, 
0.5 mM spermidine, 1 mM EDTA, 5% sucrose) and nuclei were isolated by Dounce 
homogenization of the cells followed by centrifugation. The nuclei were resuspended in 
sonication buffer (50 mM Tris-HCl pH 8.0, 2 mM EDTA, 1% SDS) and sonicated four times for 
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10 sec each at power level 5 to reduce the DNA length to 200-800 bp. After centrifugation, the 
supernatant was diluted, pre-cleared by incubation with 25% protein G-Sepharose at 4°C for 30 
min, and then incubated with 2-3 g of antibodies to FXR (Santa Cruz, H130 and C20), RXR 
(Santa Cruz, D20), or RNA Polymerase II (Santa Cruz, H224), or no antibody (mock IP), as a 
negative control, at 4
o
C overnight to immunoprecipitate the chromatin. The immune complexes 
were collected by incubation with 50 l of a 25% slurry of protein G-Sepharose for 1 h and 
washed extensively with low salt, high salt, and LiCl wash buffer followed by two washings with 
TE buffer as described previously (18). After the elution of bound chromatin, the genomic DNA 
was purified by phenol-chloroform extraction and subjected to PCR using primers specific for 
the KL promoter, or GAPDH promoter as a negative control. The PCR products were used for 
DNA gel electrophoresis and visualized with ethidium bromide staining. To validate ChIP-DNAs 
by qPCR, primers were designed specific for the peak region of two βKL binding sites, as well 
as primers for control genes. Sequences of the primers are available in the Supplemental 
Information.  
 
3.7 FXR binding motif search 
Previous ChIP-seq data were uniquely aligned to a genome that can be viewed as a 
custom track in the UCSC genome browser (http://genome.ucsc.edu). The online software 
Nubiscan and NHRScan were used to search for the FXR specific binding regions in the βKL 
gene. The FXR binding site in the 2nd βKL intron had multiple predicted binding motifs at the 
two ends of a 700 bp sequence. For luciferase reporter and gel shift analyses, fragments 
containing either the forst 195 bp or 552 bp of the 700 bp fragment were used.   
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3.8 In vitro gel mobility shift assays 
 Gel mobility shift assays were performed as previously described (41). Briefly, double 
stranded oligonucleotides (32 mers) that contain the WT or mutated predicted FXRE in the 
second intron of βKL were labeled with [γ-32P] ATP and incubated with purified FXR and 
RXR synthesized by mouse Hepac1c1 cells in the presence of 100 ng poly dIdC and 20 µg 
BSA. Binding reactions were analyzed by electrophoresis in 6% non-denaturing polyacrylamide 
gels in a low ionic Tris-acetate buffer with circulation.  
 
4. Results 
4.1 FXR binds to the βKL gene in the liver 
 Previous FXR hepatic Chip-seq data (18) generated from our lab revealed two potential 
binding sites in the first and second intron regions of βKL (Fig. 22A). To validate that FXR bind 
to these regions of the βKL gene, re-ChIP assays were carried out as described in methods 
section. Dramatically increased binding after GW4064 treatment was observed not only for FXR, 
but also for RXRα and RNA polymerase II (Pol II) to the FXR sequence corresponding to the 
FXR binding peak region within the second intron of βKL (Fig. 22B). Other than βKL, binding 
of FXR to other FGF19 signaling pathway components, including Ppp2cb1, Ppp2cb2, Ras, Raf 
and Mek was also increased after GW4064 treatment (Appendix, Fig. D1a). In a second set of re-
Chip assays, binding of FXR, RXR and Pol II was also increased to the βKL sequence in the 
first intron, and RXR and Pol II binding increased at the Ras and Ppp2cb genes (Appendix, Fig. 
D1, b-e) after GW4064 treatment. Moreover, the mRNA level of βKL, Ras and Ppp2cb genes 
increased upon GW4064 treatment (Appendix, Fig. D1f). 
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4.2 Activation of FXR signaling increased expression of βKL 
 In order to determine whether FXR indeed regulates βKL expression, mice were treated 
with a synthetic agonist of FXR, GW4064, and mRNA levels were measured. Hepatic βKL 
mRNA levels were dramatically increased after 4 h of GW4064 treatment (Fig. 23A), but 
FGFR4 mRNA levels were unchanged (Fig. 23B). Protein levels of βKL were also increased by 
GW4064 treatment (Fig. 23C-D). To establish that the GW4064 effects were FXR-dependent, 
primary mouse hepatocytes (PMH) were isolated from either FXR-null or wild type (WT) mice, 
and then treated for 3 to 4 h with GW4064. βKL mRNA levels were dramatically induced after 
GW4064 treatment in cells from WT mice, but not in those FXR-null mice (Fig. 23E). I also 
obtained primary human hepatocyte (PHH) (Liver Tissue and Cell Distribution System (LTCDS), 
University of Pittsburgh). After 3 h of treatment with either GW4064 or the primary bile acid, 
CDCA, βKL protein levels were significantly increased as determined by western blotting (Fig. 
23F). 
 
4.3 FXR is important for hepatic expression of βKL and FGF19 signaling 
 As an important membrane receptor for receiving FGF19 signaling, the expression level 
of βKL is tightly regulated. As described in Chapter 2, βKL is regulated by miR-34a, especially 
in obese state. Here I observed that βKL mRNA levels were significantly decreased in FXR-null 
mice (Fig. 24A). Accordingly, its protein level was also reduced by 50% in these mice compared 
to WT mice (Fig. 24B, C). In addition, βKL protein levels in the liver of FXR-null mice as 
detected by immunohistochemistry (IHC), were substantially reduced and the cellular location of 
was distinctly altered. FGFR4, the membrane protein co-receptor of βKL was also mis-localized 
in FXR-null mice (Fig. 24D). These data suggest that FGFR4 needs to complex with βKL to 
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locate correctly in the membrane so that the mis-localization in FXR-null mice may be due to 
decreased βKL. FXR was stained to confirm the absence of FXR expression in the FXR-null 
mice and tubulin served as a positive control. In order to confirm the inverse relationship 
between FXR and βKL expression, I overexpressed FXR by adenoviral infection in Hepa1c1c7 
cells and both βKL mRNA and protein levels were dramatically decreased (Appendix, Fig. D2, 
a-c).  
 In order to determine whether the decreased expression of βKL in FXR-null mice 
correlated with decreased FGF19 signaling in liver, primary mouse hepatocytes (PMH) were 
isolated from either FXR-null or WT mice. The cells were treated with 100 ng/ml of FGF19 or 
vehicle for 30 min, and the phosphorylation of the downstream FGF19 pathway proteins, Erk 
and Gsk, was measured by immunoblotting (Fig. 23E). The results showed that activation of Erk 
and Gsk was severely impaired in FXR-null mice. Impaired FGF19 signaling is also observed in 
high fat diet obese mice in which miR-34a levels are high because of low FXR levels. MiR-34a 
repressed βKL levels in obesity and the repression was partially reversed by anti-miR-34a 
treatment. I examined, therefore, whether downregulation of miR-34a in FXR-null mice would at 
least partially restore βKL levels. In fact, FXR-null mice treated with anti-miR-34a also resulted 
in a partial recovery of FGF19 signaling (Appendix, Fig. D3), suggesting the reduced βKL levels 
in FXR mice were partially due to elevated miR-34a levels in these mice. The role of miR-34a in 
both obesity and FXR deficient mice suggested the importance of the tightly regulation of βKL 
in normal physiological conditions as well as the pathological states.  
4.4 Identification of an FXR response element in the βKL gene 
 In order to prove that the FXR binding site was a functional transcriptional regulatory site 
for FXR, 700 bp of βKL gene, including the FXR binding region in the 2nd intron were cloned 
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into the pGL3 luciferase vector (Fig. 25A).. The vector and FXR and RXR expression plasmids 
were co-transfected into Cos-1 cells. Cells were treated for 3 h with GW4064 and luciferase 
activities were measured (Fig. 25B). Luciferase activities were increased in a dose-dependent 
manner by FXR. Then, the 700 bp fragment region was analysis by NUBIScan for potential FXR 
binding motifs and two strong sites were identified at about 100 bp and 600 bp of the 700-bp 
fragment (Appendix, Fig. D4). The first 195 bp and 552 bp, which contain the first strong site, 
but not the second were cloned separately into pGL3 luciferase vector and luciferase activities 
were measured as above (Fig. 25C-D). Neither the 195 bp nor the 552 bp fragment supported 
increased luciferase activities upon overexpression of FXR, which imply the FXRE was in the 
last 150 bp of the fragment. NHRScan software were used to predict potential FXR binding sites 
in the 2nd intron of βKL and a cluster of potential FXR binding sites, including IR-2,7, and 8, 
near 600 bp were identified (Appendix, Fig. D5). The sequence TGGGTCAAATGTCTTT was 
mutated to GCTTCGAAACGTCTTT and the 700 bp fragment with the mutation was also 
cloned into pGL3 luciferase vector. The mutation eliminated the increase in luciferase activity 
after overexpression of FXR (Fig. 25E) identifying this sequence as the FXRE.   
         To further show that the sequence in intron 2 of βKL bound to FXR, gel shift assays were 
conducted. The βKL probe containing predicted FXR motif was radio-labeled with γ-32PO4. A 
DNA fragment from Shp, a known FXR regulated gene, containing its IR-1 motif also radio-
labeled and served as a positive control. FXR and RXRα expressed in bacteria were purified and 
used to test βKL binding. The results show that FXR-RXRα-heterodimers binds to the γ-32P-
labeled βKL probe (Fig. 26, lane 2). Moreover, this binding was effectively competed by 
addition of excess βKL wt probe (lanes 3-5) while the mutant βKL probe only modestly 
competed for the binding (lanes 6-8). FXR-RXR bound effectively to the Shp probe as 
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expected (Fig. 26, lane 10-14). These results identify the sequence GGGTCAAATGTCTT as a 
functional FXRE in intron 2 of the βKL gene. 
 
4.5 The time-course of GW4064 effects on FGF19, βKL and Shp gene expression 
         I measured the time course of induction of FGF19 and βKL by FXR in vivo by 
measuring pre-mRNA levels in both liver and intestine to determine whether the time of 
induction of each was consistent with priming of the liver of response to intestinal FGF19. 
FGF19 was mainly synthesized in the intestine (300-500 fold greater than in liver) and was 
maximal in 1 to 2 h (Fig. 27A-B). In the liver the pre-mRNA of βKL increased by 30 min and 
reached a peak at 1 h (Fig. 27C), which was similar to that of the positive control, Shp (Fig. 27D). 
These preliminary in vivo time-course assay suggest that FXR increases expression of the 
FGF19 signaling components represented by βKL in the liver before inducing the synthesis of 
FGF19 in the intestine which is consistent with a role for FXR in priming the liver for FGF19 
function.  Future studies will be needed to definitively test my hypothesis that FXR works as a 
master regulator to coordinate the transcription and signaling in the gut-liver axis.  
        
5. Discussion and Future studies  
            In summary, my data so far proved that FXR/RXRα binds to the intron region of βKL 
gene and activated FXR increases the expression of βKL. βKL forms a membrane co-receptor 
complex with FGFR4 and is crucial for FGF19 signaling in the liver. FGF19 signaling in liver 
has already been shown to be crucial for maintaining bile acid homeostasis and glucose and 
protein synthesis in liver. Based on my last in vivo preliminary data, I propose that FXR induces 
the synthesis of βKL and components of the Erk signaling pathway, preparing the liver to 
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immediately respond to FGF19 signaling in liver (21), after FGF19 is synthesized in the intestine 
and is transported through the blood circulation to act at the liver (Figure. 28).  
           To test this hypothesis, some crucial time points needs to be determined: first, when 
and how FXR initiate the synthesis of βKL; second, when βKL begin to receiving the FGF19 
signaling; third, when and how FGF19 signaling begin shutting down βKL synthesis. I propose 
to use primary mouse hepatocyte (PMH) isolated form normal WT or FXR-null mice and in vivo 
experiments with WT or FXR-KO (whole-body knock out) mice or FXR-LKO (liver-specific 
knock out) or FXR-IKO (intestine-specific knock out) mice to test my hypothesis.     
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Appendix. A. Supplementary Figures and Tables for Chapter Two 
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Appendix. B. Supplementary Figures and Tables for Chapter Three 
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Appendix. C. Supplementary Figures and Tables for Chapter Four 
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Appendix. D. Supplementary Figures and Tables for Chapter Five 
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